Integrin inhibitors and uses thereof

JP2023550428A5Inactive Publication Date: 2024-11-26PLIANT THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530225
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-19
Filing Date
2021-11-19
Publication Date
2024-11-26
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current treatments for fibrotic diseases are inadequate, lacking effective long-term solutions for patient survival and symptom relief, and there is a need for new mechanisms of action to address conditions such as nonalcoholic steatohepatitis (NASH), kidney fibrosis, scleroderma, cardiac fibrosis, Crohn's disease, idiopathic pulmonary fibrosis (IPF), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC).

Method used

Development of crystalline forms of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid and its salts or solvates, which can be administered to treat or prevent fibrotic diseases by targeting αvβ6 integrins, thereby inhibiting transforming growth factor β1 (TGFβ1) activation.

Benefits of technology

The crystalline forms provide stable and bioavailable integrin inhibitors that effectively target αvβ6 integrins, potentially reducing fibrosis progression and improving patient outcomes in fibrotic diseases by inhibiting TGFβ1 activation, offering therapeutic benefits for conditions like IPF, NASH, and PSC.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Provided herein are integrin inhibitors, compositions thereof, and methods of using them. Crystalline salts of the inhibitors are described, along with methods for preparing the crystalline forms. Powder X-ray diffraction data, thermogravimetric analysis data, and differential scanning calorimetry data are provided for the crystalline forms. Integrin inhibitors are particularly useful for treating fibrotic diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] (Cross-reference of related applications) This application claims priority to U.S. Provisional Patent Application No. 63 / 116,042, filed on 19 November 2020. The entire contents of this patent application are incorporated herein by reference. [Background technology]

[0002] This disclosure provides integrin inhibitors, compositions thereof, and methods of using them.

[0003] Fibrosis is a pathological feature of many diseases, caused by a dysfunction in the body's natural ability to repair damaged tissue. If left untreated, fibrosis can lead to scarring of vital organs, resulting in irreparable damage and ultimately organ failure.

[0004] Patients with non-alcoholic fatty liver disease (NAFLD) may progress from simple fatty liver to non-alcoholic steatohepatitis (NASH), and then to fibrosis. While liver fibrosis is reversible in its early stages, progressive liver fibrosis can lead to cirrhosis.

[0005] Renal fibrosis, characterized by glomerulosclerosis and tubulointerstitial fibrosis, is the ultimate common symptom of a wide variety of chronic kidney diseases (CKD). Regardless of the initial cause, progressive CKD often leads to extensive tissue scarring, destruction of the renal parenchyma, and end-stage renal failure, a catastrophic condition requiring dialysis or kidney replacement.

[0006] Scleroderma encompasses a complex and diverse range of conditions primarily characterized by fibrosis, vascular changes, and autoimmunity. The disease scope of scleroderma is characterized by a common feature of fibrosis, which leads to hardening and thickening of the skin. This hardening may occur only in limited areas in some patients, but can spread to other major organs in others.

[0007] Cardiac structural remodeling after myocardial infarction is associated with an inflammatory response that results in scar formation at the site of infarction. This scar formation is a result of fibrotic tissue deposition that can lead to a decline in cardiac function and disruption of electrical activity within the heart.

[0008] Crohn's disease is a chronic disease of unknown cause that tends to progress despite medical or surgical treatment. Intestinal fibrosis is one of the most common complications of Crohn's disease in which strictures form in the small intestine and colon.

[0009] Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive fibrotic disease of unknown cause that develops in adults and is limited to the lungs. In IPF, lung tissue thickens, hardens, and scars. As pulmonary fibrosis progresses, the lungs have difficulty delivering oxygen to the bloodstream, and the organs are unable to receive the oxygen needed to function properly. IPF currently affects approximately 200,000 people in the United States and results in 40,000 deaths annually. Patients diagnosed with IPF experience progressive shortness of breath and ultimately complete respiratory failure.

[0010] Primary biliary cholangitis (PBC), also known as primary biliary cirrhosis, is a chronic disease of the liver that causes liver damage and fibrosis. It is a state of cholestasis in which bile and other toxins accumulate in the liver, and progressive destruction occurs slowly in the small bile ducts of the liver. Over time, scarring and fibrosis are caused in both the liver and the biliary tract.

[0011] Non-specific interstitial pneumonia (NSIP) is a rare disease that affects the tissue surrounding and separating the small air sacs of the lungs. These air sacs, called alveoli, are the sites where oxygen and carbon dioxide are exchanged between the lungs and the bloodstream. Interstitial pneumonia is a disease in which the mesh-like walls of the alveoli become inflamed. The pleura, a thin membrane that protects and cushions the lungs and individual lung lobes, can also become inflamed. NSIP has two main forms: cellular and fibrotic. The cellular form is mainly defined by inflammation of the interstitial cells. The fibrotic form is defined by thickening and scarring of the lung tissue. This scarring, known as fibrosis, is irreversible. When the lung tissue thickens or scars, the function of the lungs is effectively impaired. The efficiency of breathing deteriorates, and the level of oxygen in the blood decreases (Kim et al., Proc. Am. Thorac. Soc. (2006) 3:285-292; Lynch, D., Radiology (2001) 221:583-584; Kinder et al., Am. J. Respir. Crit. Care Med. (2007) 176:691-697).

[0012] Currently, available treatment courses are not sufficient because there is no proven option on the market that is effective for long-term patient survival or symptoms. The need for treatment of fibrotic diseases still exists.

[0013] αvβ6 integrin is expressed in epithelial cells, binds to the latent associated peptide of transforming growth factor β1 (TGFβ1), and mediates the activation of TGFβ1. Its expression level increases significantly after injury to lung and bile duct cells and plays an important role in vivo in tissue fibrosis. The increased expression level is also associated with an increased mortality rate in patients with IPF and NSIP.

[0014] Primary sclerosing cholangitis (PSC) involves inflammation of the bile ducts and fibrosis that obstructs the bile ducts. The resulting impaired bile flow to the intestines can lead to complications such as cirrhosis and subsequent liver failure and liver cancer. αvβ6 expression is elevated in the liver and bile ducts of PSC patients.

[0015] There remains a strong need for drugs that explore novel mechanisms of action and can deliver better short- and long-term outcomes in terms of symptom relief, safety, and patient mortality. US 20190276449 discloses (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid, an αvβ6 integrin inhibitor that offers therapeutic potential for fibrosis, all of which are incorporated herein by reference.

[0016] For drug candidates such as (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthirizine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid to be commercialized as pharmaceuticals, it is considered important to understand the relative stability and interconversion of these forms under conditions facing large-scale manufacturing, transportation, storage, and pre-use preparation, whether the drug candidate exists in crystalline form or not. The ability to control and manufacture stable crystals under rigorous manufacturing processes may be important for regulatory approval and commercialization. Large-scale manufacturing methods for high-purity (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthirizine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid can be improved by using specific crystals. Therefore, there is a need for various novel crystalline forms of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid with different chemical and physical stabilities, as well as for their compositions and applications.

[0017] (Summary of the invention) In one embodiment, the present invention provides crystalline salts or solvates of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid as detailed herein.

[0018] In another embodiment, the present invention provides a method for producing crystalline salts or solvates of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid, as detailed herein.

[0019] In another embodiment, the present invention provides a composition comprising a salt of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid or a solvate thereof, as detailed herein.

[0020] In another embodiment, the present invention provides a kit comprising a salt of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid or a solvate thereof, as detailed herein.

[0021] In another embodiment, a method is provided for treating a fibrotic disease in an individual (e.g., a human) requiring treatment of the fibrotic disease, the method comprising administering a therapeutically effective amount of the crystalline or composition disclosed herein to the individual. In one embodiment, the fibrosis is pulmonary fibrosis (e.g., IPF), hepatic fibrosis, cutaneous fibrosis, scleroderma, cardiac fibrosis, renal fibrosis, gastrointestinal fibrosis, primary sclerosing cholangitis, or cholangiofibrosis (e.g., PBC).

[0022] In another embodiment, a method is provided for delaying the onset and / or development of a fibrous disease in an individual at risk of developing a fibrous disease (e.g., a human), characterized by administering a therapeutically effective amount of the crystalline or composition disclosed herein to the individual. In one embodiment, the fibrosis is pulmonary fibrosis (e.g., IPF), hepatic fibrosis, cutaneous fibrosis, scleroderma, cardiac fibrosis, renal fibrosis, gastrointestinal fibrosis, primary sclerosing cholangitis, or PBC. In one embodiment, the individual at risk of developing a fibrous disease is an individual who has or is suspected of having NAFLD, NASH, CKD, scleroderma, Crohn's disease, NSIP, PSC, PBC, or an individual who has had or is suspected of having had a myocardial infarction.

[0023] Furthermore, crystals or compositions for use in the treatment of fibrous diseases are provided. The use of crystals or compositions for use in the treatment of fibrous diseases is also provided. The use of crystals or compositions for use in the manufacture of pharmaceuticals for the treatment of fibrous diseases is also provided. [Brief explanation of the drawing]

[0024] [Figure 1A] Figure 1A shows the experimental powder X-ray diffraction (XRPD) patterns of the crystalline form (Form I) of the phosphate salt of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid (Form I) (from top to bottom: Form I prepared on a 20 mg scale, Form I prepared on a 100 mg scale, Form I prepared on a 1 g scale, and Form I prepared on a 4.5 g scale). [Figure 1B] Figure 1B shows graphs of differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) of Form I prepared on a 20 mg scale. [Figure 1C] Figure 1C shows graphs of DSC and TGA of Form I manufactured on a 100 mg scale. [Figure 1D] Figure 1D shows graphs of DSC and TGA of morphology I manufactured on a 1g scale. [Figure 1E] Figure 1E shows graphs of DSC and TGA of morphology I manufactured on a 4.5g scale. [Figure 1F] Figure 1F shows a graph of the dynamic water vapor adsorption (DVS) method for Form I, manufactured on a 4.5g scale. [Figure 2A] Figure 2A shows the experimental XRPD patterns of the crystalline form (Form II) of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid fumarate (Top: Form II prepared on a 100 mg scale, Bottom: Form II prepared on a 20 mg scale). [Figure 2B] Figure 2B shows graphs of DSC and TGA of Form II manufactured on a 100 mg scale. [Figure 2C] Figure 2C shows the XRPD pattern of Form II before heating to 150°C and the XRPD pattern of Form II after heating to 150°C (top: before heating to 150°C, bottom: after heating to 150°C). [Figure 3A] Figure 3A shows the experimental XRPD pattern (top: form III) of the crystalline form (form III) of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid 1,5-naphthalenedisulfonate. [Figure 3B] Figure 3B shows graphs of DSC and TGA for morphology III. [Figure 4] Figure 4 shows experimental and simulated XRPD patterns (Morphology IV) of the crystalline isopropyl alcohol and water mixed solvate of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid phosphate. Detailed description of the invention

[0025] (definition) Where used herein, unless otherwise specified, terms such as "a," "an," etc., mean one or more.

[0026] Where used herein, any reference to “about” a value or parameter includes (and describes) embodiments relating to the value or parameter itself. For example, a statement referring to “about X” includes a statement of “X.” Where used herein and unless otherwise specified, the terms “about” and “approximately” mean, when used in relation to a dose, volume or weight percentage relating to an ingredient of a composition or dosage form, a dose, volume or weight percentage that is recognized by those skilled in the art as providing an equivalent pharmacological effect to that obtained from a specified dose, volume or weight percentage. Specifically, where used in this context, the terms “about” and “approximately” refer to doses, volumes or weight percentages within 20%, 15%, 10%, 5%, 4%, 3%, 2%, 1%, or 0.5% of a specified dose, volume or weight percentage.

[0027] As used herein, the term “crystalline form” refers to the crystalline solid form of a compound, including, but not limited to, single-component or multi-component crystalline forms, such as polymorphs of a compound; or solvates, hydrates, clathrates, cocrystals, salts of a compound, or their polymorphs. In this specification, “crystalline form” and related terms mean various crystalline modifications of a given substance, including, but not limited to, polymorphs, solvates, hydrates, cocrystals, and other molecular complexes, as well as salts, solvates of salts, hydrates of salts, other molecular complexes of salts, and their polymorphs. The crystalline forms of substances can be obtained by many methods, as is known in the art. Such methods include, but are not limited to, melt recrystallization, melt cooling, solvent recrystallization, slurrying, recrystallization in confined spaces (e.g., nanopores or capillaries), recrystallization on surfaces or templates such as polymers, recrystallization in the presence of additives (e.g., poor solvents, cocrystal pair molecules), desolvation, dehydration, rapid evaporation, rapid cooling, slow cooling, vapor diffusion, coagulation, grinding, and solvent drop-in grinding.

[0028] As used herein, “solvate” encompasses solvates, partial solvates, and channel solvates. Such solvates do not need to contain the exact stoichiometric ratio of compound:solvent, but may contain a compound:solvent ratio that is acceptable as an experimental error. The term “solvate” is further intended to include aqueous and non-aqueous solvates (e.g., hydrates, ethanol hydrates, etc.). Therefore, it is understood that solvates encompass stoichiometric solvates, channel solvates, and partial solvates. Similarly, it is understood that hydrates encompass stoichiometric hydrates, channel hydrates, and partial hydrates. An example of a phosphate solvate is channel hydrate.

[0029] As used herein, "individual" refers to a mammal unless otherwise specified, and includes, but is not limited to, primates, humans, cattle, horses, cats, dogs, or rodents. One variation is that the individual is a human.

[0030] As used herein, “treatment” or “treating” means an approach to obtain a beneficial or desired outcome, which includes clinical outcomes. Beneficial or desired outcomes include, but are not limited to, one or more of the following: reducing one or more symptoms caused by the disease; reducing the severity of the disease; stabilizing the disease (e.g., preventing or delaying disease exacerbation); preventing or delaying the spread of the disease; delaying the onset or recurrence of the disease; delaying or slowing the progression of the disease; alleviating the condition; providing remission (partial or total) of the disease; reducing the dose of one or more other drugs required to treat the disease; enhancing the effect of another drug; delaying disease progression; improving quality of life; and / or extending survival. “Treatment” also includes mitigating the pathological outcomes of fibrosis. The methods of the present invention aim to achieve one or more of these forms of treatment.

[0031] As used herein, the term “effective dose” means the amount of the compound of the present invention that can be effective in a given therapeutic form. As understood in the art, an effective dose may exist in one or more doses; that is, a single dose or multiple doses may be required to achieve a desired therapeutic endpoint. An effective dose may be considered in connection with the administration of one or more therapeutic agents (e.g., the compound or a pharmaceutically acceptable salt thereof), but a single agent may be considered administered in an effective dose if the desired or beneficial outcome can be achieved, or is achieved, in combination with one or more other agents. The preferred dose of any of the co-administered compounds may be reduced as desired due to the combined action of the compounds (e.g., additive or synergistic effect).

[0032] As used herein, “therapeutic dose” means the amount of the compound or a salt thereof that is sufficient to produce the desired therapeutic effect.

[0033] As used herein, “unit dosage form” means a physically distinct unit suitable as a unit dose, each unit containing a predetermined amount of the active ingredient calculated to produce the desired therapeutic effect in conjunction with the required pharmaceutical carrier. Unit dosage forms may include monotherapy or combination therapy.

[0034] As used herein, the term “controlled release” refers to a drug-containing formulation (i.e., a “controlled release” formulation) or a part thereof in which the drug is not released immediately into the absorption pool during administration. The term encompasses depot formulations designed to release the drug compound gradually over a long period of time. Controlled release formulations can encompass a wide variety of drug delivery systems, and generally involve mixing the drug compound with a carrier, polymer, or other compound having desired release properties (e.g., pH-dependent or non-pH-dependent solubility, different degrees of water solubility, etc.) and formulating the mixture according to a desired delivery route (e.g., coated capsules, embedded reservoirs, injectable solutions containing biodegradable capsules, etc.).

[0035] As used herein, “pharmaceutically acceptable” or “pharmacologically acceptable” means that a material is not biologically or otherwise undesirable, for example, that can be incorporated into a pharmaceutical composition administered to a patient without causing significant undesirable biological effects or adverse interactions with any of the other components of the composition in which it is contained. pharmaceutically acceptable carriers or excipients preferably meet the required standards for toxicity and manufacturing testing and / or are included in the inactive ingredient guideline created by the U.S. Food and Drug Administration.

[0036] As used herein, the term "excipient" means an inert or non-active substance that can be used in the manufacture of a drug or pharmaceutical, such as a tablet, containing the compound of the present invention as an active ingredient. The term excipient may include, but is not limited to, various substances used as binders, disintegrants, coatings, compression / encapsulation aids, creams or lotions, lubricants, parenteral solutions, chewable tablet materials, sweeteners or flavoring / odorizing agents, suspension / gelling agents, or wet granulation agents. Examples of binders include carbomer, povidone, and xanthan gum; examples of coating agents include cellulose phthalate acetate, ethylcellulose, gellan gum, maltodextrin, and enteric coatings; examples of compression / encapsulation aids include calcium carbonate, dextrose, fructose dc (dc = "directly compressible"), honey dc, lactose (anhydrous or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch dc, and sucrose; examples of disintegrants include croscarmellose sodium, gellan gum, and sodium starch glycolate; and examples of creams or lotions include... Examples of lubricants include maltodextrin and carrageenan; examples of lubricants include magnesium stearate, stearic acid, and sodium stearyl fumarate; examples of chewable tablet materials include dextrose, fructose dc, and lactose (monohydrate, optionally combined with aspartame or cellulose); examples of suspending / gelling agents include carrageenan, sodium starch glycolate, and xanthan gum; examples of sweeteners include aspartame, dextrose, fructose dc, sorbitol, and sucrose dc; and examples of wet granulating agents include calcium carbonate, maltodextrin, and microcrystalline cellulose.

[0037] Unless otherwise stated, "substantially pure" means a composition containing approximately 10% or less impurities, such as compositions containing less than approximately 9%, 7%, 5%, 3%, 1%, or 0.5% impurities.

[0038] The embodiments and models described herein as "including" are understood to encompass embodiments that "consist of" and "essentially consist of."

[0039] When used herein, if an XRPD pattern, DSC graph, TGA graph, or GVS graph is cited, the term “substantially as shown” does not necessarily have to be identical to the one depicted herein, but includes patterns or graphs that, as considered by a person skilled in the art, fall within the range of experimental error or deviation.

[0040] Crystal In one embodiment, this specification describes the following structure: [ka] The present invention provides a crystalline form of a salt or solvate of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid, which is a compound having the above properties.

[0041] As used herein, the term "parent compound" refers to the salt-free form of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid. Similarly, the notation of "(S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid" alone or its structural formula alone refers to the parent compound unless otherwise stated or explicitly indicated in the context in which the wording is used.

[0042] The crystalline materials disclosed herein may offer advantages in terms of bioavailability and stability and may be suitable for use as active agents in pharmaceutical compositions. Variations in the crystalline structure of a pharmaceutical raw material may affect the dissolution rate (which may affect bioavailability, etc.), manufacturability (e.g., ease of handling, ease of purification, ability to consistently produce doses of known strength, etc.), and stability (e.g., thermal stability and shelf life, e.g., resistance to degradation, etc.) of the pharmaceutical raw material. Such variations may affect the manufacturing method or formulation of pharmaceutical compositions into various dosage forms or delivery forms (e.g., solid oral dosage forms such as tablets and capsules). Compared to other forms such as amorphous or noncrystalline forms, crystalline materials may offer desired or suitable hygroscopicity, particle size control, dissolution rate, solubility, purity, physical and chemical stability, manufacturability, yield, reproducibility, and / or process control. Accordingly, the crystalline materials disclosed herein may offer advantages in improving the manufacturing process of active agents or the stability or shelf life of the pharmaceutical form of the active agent, or advantages in having appropriate bioavailability and / or stability as an active agent.

[0043] phosphate crystals In one embodiment, this specification provides a crystalline form (Form I) of the phosphate salt of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid.

[0044] In one embodiment, morphology I has an XRPD pattern substantially as shown in Figure 1A. Table 1 shows the peak positions and relative peak intensities that can be observed for the crystal using XRPD.

[0045] [Table 1]

[0046] In one embodiment, morphology I has an XRPD pattern containing the peaks shown in Table 1. In one embodiment, morphology I has an XRPD pattern substantially shown in Figure 1A or as shown in Table 1, containing one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks having maximum intensity at angle 2θ. It should be understood that relative intensity and peak identification can vary due to many factors, including sample preparation, mounting, instruments and analytical methods and settings used to obtain the spectrum, temperature affecting the unit cell and the degree of solvation of the sample (e.g., degree of hydration). For example, relative peak intensity and peak identification can vary within the range of experimental error. In one embodiment, the identification of each peak listed herein can vary independently, for example, ±0.6°, ±0.4°, ±0.2°, or ±0.1°2θ for morphology I. In one embodiment, the identification of each peak described herein may vary independently up to ±0.2°2θ for morphology I, for example.

[0047] In one embodiment, form I has an XRPD pattern including peaks identified at angles 2θ(°) as listed in Table 1, and each of these peaks may vary independently in the identification of angle 2θ(°) as described herein. For example, for morphology I, the values ​​are approximately 4.31 (e.g., 4.31 ± 0.2), approximately 6.76 (e.g., 6.76 ± 0.2), approximately 8.55 (e.g., 8.55 ± 0.2), approximately 10.04 (e.g., 10.04 ± 0.2), approximately 11.25 (e.g., 11.25 ± 0.2), approximately 12.75 (e.g., 12.75 ± 0.2), approximately 13.76 (e.g., 13.76 ± 0.2), approximately 17.20 (e.g., 17.20 ± 0.2), approximately 18.02 (e.g., 18.02 ± 0.2), approximately 18.89 (e.g., 18.89 ± 0.2), and approximately 20.38. The XRPD pattern may have peaks identified at angles 2θ(°) of approximately 20.38±0.2, 21.29(e.g., 21.29±0.2), 23.16(e.g., 23.16±0.2), 23.97(e.g., 23.97±0.2), 24.68(e.g., 24.68±0.2), 25.50(e.g., 25.50±0.2), 26.18(e.g., 26.18±0.2), 29.88(e.g., 29.88±0.2), and 33.49(e.g., 33.49±0.2).In one embodiment, form I has one or more peaks (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) identified at angles 2θ(°): approximately 4.31 (e.g., 4.31±0.2), approximately 6.76 (e.g., 6.76±0.2), approximately 8.55 (e.g., 8.55±0.2), approximately 10.04 (e.g., 10.04±0.2), approximately 11.25 (e.g., 11.25±0.2), approximately 12.75 (e.g., 12.75±0.2), approximately 13.76 (e.g., 13.76±0.2), approximately 17 The XRPD pattern includes values ​​such as 0.20 (e.g., 17.20±0.2), approximately 18.02 (e.g., 18.02±0.2), approximately 18.89 (e.g., 18.89±0.2), approximately 20.38 (e.g., 20.38±0.2), approximately 21.29 (e.g., 21.29±0.2), approximately 23.16 (e.g., 23.16±0.2), approximately 23.97 (e.g., 23.97±0.2), approximately 24.68 (e.g., 24.68±0.2), approximately 25.50 (e.g., 25.50±0.2), approximately 26.18 (e.g., 26.18±0.2), approximately 29.88 (e.g., 29.88±0.2), and approximately 33.49 (e.g., 33.49±0.2). In one embodiment, form I has an XRPD pattern that includes peaks identified at angles 2θ(°) of approximately 4.31 (e.g., 4.31±0.2), approximately 6.76 (e.g., 6.76±0.2), approximately 11.25 (e.g., 11.25±0.2), approximately 12.75 (e.g., 12.75±0.2), approximately 18.89 (e.g., 18.89±0.2), approximately 20.38 (e.g., 20.38±0.2), approximately 21.29 (e.g., 21.29±0.2), approximately 23.16 (e.g., 23.16±0.2), approximately 23.97 (e.g., 23.97±0.2), and approximately 24.68 (e.g., 24.68±0.2).In one embodiment, form I has one or more peaks (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) identified at angles 2θ(°): approximately 4.31 (e.g., 4.31 ± 0.2), approximately 6.76 (e.g., 6.76 ± 0.2), and approximately 11.25 (e.g., 11 It has an XRPD pattern including approximately 0.25±0.2), approximately 12.75 (e.g., 12.75±0.2), approximately 18.89 (e.g., 18.89±0.2), approximately 20.38 (e.g., 20.38±0.2), approximately 21.29 (e.g., 21.29±0.2), approximately 23.16 (e.g., 23.16±0.2), approximately 23.97 (e.g., 23.97±0.2), and approximately 24.68 (e.g., 24.68±0.2). In one embodiment, form I has an XRPD pattern that includes peaks identified at angles 2θ(°) of approximately 4.31 (e.g., 4.31±0.2), approximately 6.76 (e.g., 6.76±0.2), approximately 18.89 (e.g., 18.89±0.2), approximately 21.29 (e.g., 21.29±0.2), and approximately 23.16 (e.g., 23.16±0.2). In one embodiment, morphology I has an XRPD pattern including one or more peaks (e.g., at least one, at least two, at least three, at least four, or at least five) identified at angles 2θ(°): approximately 4.31 (e.g., 4.31±0.2), approximately 6.76 (e.g., 6.76±0.2), approximately 18.89 (e.g., 18.89±0.2), approximately 21.29 (e.g., 21.29±0.2), and approximately 23.16 (e.g., 23.16±0.2). In one embodiment, morphology I has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.31±0.2, 6.76±0.2, 18.89±0.2, 21.29±0.2, and 23.16±0.2. In another embodiment, morphology I has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.31, 6.76, 11.25, and 12.75.In one embodiment, morphology I has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.31±0.2, approximately 6.76±0.2, approximately 11.25±0.2, and approximately 12.75±0.2. In one embodiment, morphology I has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.31, approximately 6.76, and approximately 11.25. In one embodiment, morphology I has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.31±0.2, approximately 6.76±0.2, and approximately 11.25±0.2. In one embodiment, morphology I has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.31, approximately 6.76, and approximately 12.75. In one embodiment, morphology I has an XRPD pattern including peaks identified at angles 2θ of approximately 4.31±0.2, approximately 6.76±0.2, and approximately 12.75±0.2. In one embodiment, morphology I has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.31 and approximately 6.76. In one embodiment, morphology I has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.31±0.2 and approximately 6.76±0.2. In one embodiment, morphology I has an XRPD pattern including a peak identified at angle 2θ(°) of approximately 4.31. In one embodiment, morphology I has an XRPD pattern including a peak identified at angle 2θ(°) of approximately 4.31±0.2.

[0048] In one embodiment, form I has a DSC graph substantially as shown in Figure 1B, Figure 1C, Figure 1D, or Figure 1E. In one embodiment, form I has a DSC graph substantially as shown in Figure 1B. In one embodiment, form I is characterized by having endothermic peaks at approximately 88.3°C, 136.3°C, and / or approximately 197.6°C, as measured by DSC. In one embodiment, form I has a DSC graph substantially as shown in Figure 1C. In one embodiment, form I is characterized by having endothermic peaks at approximately 86.1°C, approximately 140.8°C, and / or approximately 197.0°C, as measured by DSC. In one embodiment, form I has a DSC graph substantially as shown in Figure 1D. In one embodiment, form I is characterized by having endothermic peaks at approximately 77.3°C, 132.2°C, and / or approximately 197.0°C, as measured by DSC. In one embodiment, form I has a DSC graph substantially as shown in Figure 1E. In one embodiment, form I is characterized by having endothermic peaks at approximately 95.2°C, approximately 134.1°C, and / or approximately 200.9°C, as measured by DSC.

[0049] In one embodiment, form I has a TGA graph substantially as shown in Figure 1B, Figure 1C, Figure 1D, or Figure 1E. In one embodiment, form I has a TGA graph substantially as shown in Figure 1B. In one embodiment, form I is characterized by exhibiting a weight loss of about 5.21% after heating from about 26.5°C to about 150.0°C, as measured by TGA. In one embodiment, form I has a TGA graph substantially as shown in Figure 1C. In one embodiment, form I is characterized by exhibiting a weight loss of about 5.04% after heating from about 27.0°C to about 110.0°C, as measured by TGA. In one embodiment, form I has a TGA graph substantially as shown in Figure 1D. In one embodiment, form I is characterized by exhibiting a weight loss of about 10.32% after heating from about 30.0°C to about 150.0°C, as measured by TGA. In one embodiment, form I has a TGA graph substantially as shown in Figure 1E. In one embodiment, form I is characterized by exhibiting a weight loss of approximately 7.37% after heating from approximately 27.0°C to approximately 150.0°C, as measured by TGA.

[0050] In one embodiment, form I has a DVS graph substantially as shown in Figure 1F.

[0051] In one embodiment of Form I, at least one, at least two, at least three, at least four, at least five, at least six, or all of the following (a) to (g) apply: (a) Morphology I has an XRPD pattern that includes the following peaks: (i) Peaks at angles 2θ of approximately 4.31° (e.g., 4.31±0.2), approximately 6.76° (e.g., 6.76±0.2), approximately 18.89° (e.g., 18.89±0.2), approximately 21.29° (e.g., 21.29±0.2), and approximately 23.16° (e.g., 23.16±0.2); (ii) Peaks at angles 2θ of approximately 4.31° (e.g., 4.31±0.2), approximately 6.76° (e.g., 6.76±0.2), approximately 11.25° (e.g., 11.25±0.2), approximately 12.75° (e.g., 12.75±0.2), approximately 18.89° (e.g., 18.89±0.2), approximately 20.38° (e.g., 20.38±0.2), approximately 21.29° (e.g., 21.29±0.2), approximately 23.16° (e.g., 23.16±0.2), approximately 23.97° (e.g., 23.97±0.2), and approximately 24.68° (e.g., 24.68±0.2); or (iii) Approximately 4.31° (e.g., 4.31±0.2), approximately 6.76° (e.g., 6.76±0.2), approximately 8.55° (e.g., 8.55±0.2), approximately 10.04° (e.g., 10.04±0.2), approximately 11.25° (e.g., 11.25±0.2), approximately 12.75° (e.g., 12.75±0.2), approximately 13.76° (e.g., 13.76±0.2), approximately 17.20° (e.g., 17.20±0.2), approximately 18.02° (e.g., 18.02±0.2), approximately 18.89° (e.g., 18.89±0.2). 2) Peaks at angles 2θ of approximately 20.38° (e.g., 20.38±0.2), approximately 21.29° (e.g., 21.29±0.2), approximately 23.16° (e.g., 23.16±0.2), approximately 23.97° (e.g., 23.97±0.2), approximately 24.68° (e.g., 24.68±0.2), approximately 25.50° (e.g., 25.50±0.2), approximately 26.18° (e.g., 26.18±0.2), approximately 29.88° (e.g., 29.88±0.2), and approximately 33.49° (e.g., 33.49±0.2); (b) Morphology I has an XRPD pattern substantially as shown in Figure 1A; (c) Form I has a DSC graph substantially as shown in Figure 1B, Figure 1C, Figure 1D, or Figure 1E; (d) Form I is characterized by having endothermic peaks of approximately 88.3°C, approximately 136.3°C and / or approximately 197.6°C as measured by DSC; endothermic peaks of approximately 86.1°C, approximately 140.8°C and / or approximately 197.0°C as measured by DSC; endothermic peaks of approximately 77.3°C, 132.2°C and / or approximately 197.0°C as measured by DSC; or endothermic peaks of approximately 95.2°C, approximately 134.1°C and / or approximately 200.9°C as measured by DSC; (e) Form I has a TGA graph substantially as shown in Figure 1B, Figure 1C, Figure 1D, or Figure 1E; (f) Form I is characterized by exhibiting a weight loss of approximately 5.21% after heating from approximately 26.5°C to approximately 150.0°C as measured by TGA, a weight loss of approximately 5.04% after heating from approximately 27.0°C to approximately 110.0°C as measured by TGA, a weight loss of approximately 10.32% after heating from approximately 30.0°C to approximately 150.0°C as measured by TGA, or a weight loss of approximately 7.37% after heating from approximately 27.0°C to approximately 150.0°C as measured by TGA; and (g) Form I has a DVS graph substantially as shown in Figure 1F.

[0052] Fumarate crystals In one embodiment, the Spectrum provides a crystalline form (Form II) of the fumarate of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid.

[0053] In one embodiment, form II has an XRPD pattern substantially as shown in Figure 2A. Table 2 shows the peak positions and relative peak intensities that can be observed for the crystal using XRPD. [Table 2] [Table 3]

[0054] In one embodiment, morphology II has an XRPD pattern containing the peaks shown in Table 2. In one embodiment, morphology II has an XRPD pattern substantially shown in Figure 2A or as shown in Table 2, containing one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks having maximum intensity at angle 2θ. It should be understood that relative intensity and peak identification can vary due to many factors, including sample preparation, mounting, instruments and analytical methods and settings used to obtain the spectrum, temperature affecting the unit cell and the degree of solvation of the sample (e.g., degree of hydration). For example, relative peak intensity and peak identification can vary within the range of experimental error. In one embodiment, the identification of each peak listed herein can vary independently, for example, ±0.6°, ±0.4°, ±0.2°, or ±0.1°2θ for morphology II. In one embodiment, the identification of each peak described herein may vary independently by ±0.2°2θ for, for example, morphology II.

[0055] In one embodiment, form II has an XRPD pattern including peaks identified at angles 2θ(°) as listed in Table 2, and each of these peaks may vary independently in the identification of angle 2θ(°) as described herein. For example, for Form II, the values ​​are approximately 6.87 (e.g., 6.87±0.2), approximately 8.47 (e.g., 8.47±0.2), approximately 9.37 (e.g., 9.37±0.2), approximately 10.51 (e.g., 10.51±0.2), approximately 12.20 (e.g., 12.20±0.2), approximately 12.63 (e.g., 12.63±0.2), approximately 13.34 (e.g., 13.34±0.2), approximately 13.98 (e.g., 13.98±0.2), approximately 16.20 (e.g., 16.20±0.2), approximately 17.26 (e.g., 17.26±0.2), and approximately 18.11 (e.g., 18.11 The XRPD pattern may have peaks identified at angles 2θ(°) of approximately ±0.2, 18.72 (e.g., 18.72±0.2), 19.42 (e.g., 19.42±0.2), 20.46 (e.g., 20.46±0.2), 21.87 (e.g., 21.87±0.2), 22.15 (e.g., 22.15±0.2), 23.70 (e.g., 23.70±0.2), 24.01 (e.g., 24.01±0.2), 24.43 (e.g., 24.43±0.2), and 25.59 (e.g., 25.59±0.2).In one embodiment, form II has one or more peaks (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) identified at each angle 2θ(°): approximately 6.87 (e.g., 6.87±0.2), approximately 8.47 (e.g., 8.47±0.2), approximately 9.37 (e.g., 9.37±0.2), approximately 10.51 (e.g., 10.51±0.2), approximately 12.20 (e.g., 12.20±0.2), approximately 12.63 (e.g., 12.63±0.2), approximately 13.34 (e.g., 13.34±0.2), approximately 13.98 (e.g., 13. 98±0.2), approximately 16.20 (e.g., 16.20±0.2), approximately 17.26 (e.g., 17.26±0.2), approximately 18.11 (e.g., 18.11±0.2), approximately 18.72 (e.g., 18.72±0.2), approximately 19.42 (e.g., 19.42±0.2), approximately 20.46 (e.g., 20.46±0.2), approximately 21. It has an XRPD pattern including 87 (e.g., 21.87±0.2), approximately 22.15 (e.g., 22.15±0.2), approximately 23.70 (e.g., 23.70±0.2), approximately 24.01 (e.g., 24.01±0.2), approximately 24.43 (e.g., 24.43±0.2), and approximately 25.59 (e.g., 25.59±0.2). In one embodiment, form II has an XRPD pattern that includes peaks identified at angles 2θ(°) of approximately 8.47 (e.g., 8.47±0.2), approximately 9.37 (e.g., 9.37±0.2), approximately 10.51 (e.g., 10.51±0.2), approximately 13.98 (e.g., 13.98±0.2), approximately 16.20 (e.g., 16.20±0.2), approximately 17.26 (e.g., 17.26±0.2), approximately 23.70 (e.g., 23.70±0.2), approximately 24.01 (e.g., 24.01±0.2), approximately 24.43 (e.g., 24.43±0.2), and approximately 25.59 (e.g., 25.59±0.2).In one embodiment, form II has one or more peaks (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) identified at angles 2θ(°): approximately 8.47 (e.g., 8.47 ± 0.2), approximately 9.37 (e.g., 9.37 ± 0.2), approximately 10.51 (e.g., 10 It has an XRPD pattern including approximately 0.51±0.2), approximately 13.98 (e.g., 13.98±0.2), approximately 16.20 (e.g., 16.20±0.2), approximately 17.26 (e.g., 17.26±0.2), approximately 23.70 (e.g., 23.70±0.2), approximately 24.01 (e.g., 24.01±0.2), approximately 24.43 (e.g., 24.43±0.2), and approximately 25.59 (e.g., 25.59±0.2). In one embodiment, form II has an XRPD pattern that includes peaks identified at angles 2θ(°) of approximately 8.47 (e.g., 8.47±0.2), approximately 10.51 (e.g., 10.51±0.2), approximately 13.98 (e.g., 13.98±0.2), approximately 23.70 (e.g., 23.70±0.2), and approximately 24.43 (e.g., 24.43±0.2). In one embodiment, form II has an XRPD pattern including one or more peaks (e.g., at least one, at least two, at least three, at least four, or at least five) identified at angles 2θ(°): approximately 8.47 (e.g., 8.47±0.2), approximately 10.51 (e.g., 10.51±0.2), approximately 13.98 (e.g., 13.98±0.2), approximately 23.70 (e.g., 23.70±0.2), and approximately 24.43 (e.g., 24.43±0.2). In one embodiment, form II has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 8.47, approximately 9.37, approximately 10.51, and approximately 13.98. In one embodiment, form II has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 8.47±0.2, 9.37±0.2, 10.51±0.2, and 13.98±0.2.In one embodiment, form II has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 8.47±0.2, approximately 9.37±0.2, and approximately 10.51±0.2. In one embodiment, form II has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 8.47, approximately 9.37, and approximately 13.98. In one embodiment, form II has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 8.47±0.2, approximately 9.37±0.2, and approximately 13.98±0.2. In one embodiment, form II has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 8.47 and approximately 9.37. In one embodiment, form II has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 8.47±0.2 and approximately 9.37±0.2. In one embodiment, morphology II has an XRPD pattern that includes a peak identified at an angle 2θ(°) of approximately 8.47°. In another embodiment, morphology II has an XRPD pattern that includes a peak identified at an angle 2θ(°) of approximately 8.47±0.2°.

[0056] In one embodiment, form II has a DSC graph substantially as shown in Figure 2B. In one embodiment, form II is characterized by having an endothermic peak at approximately 95.4°C.

[0057] In one embodiment, form II has a TGA graph substantially as shown in Figure 2B. In one embodiment, form II is characterized by exhibiting a weight loss of about 13.02% after heating from about 26.0°C to about 125.0°C, as measured by TGA.

[0058] In one embodiment of Form II, at least one, at least two, at least three, at least four, at least five, or all of the following (a) to (f) apply: (a) Morphology II has an XRPD pattern that includes the following peaks: (i) Peaks at angles 2θ of approximately 8.47° (e.g., 8.47±0.2), approximately 10.51° (e.g., 10.51±0.2), approximately 13.98° (e.g., 13.98±0.2), approximately 23.70° (e.g., 23.70±0.2), and approximately 24.43° (e.g., 24.43±0.2): (ii) Peaks at angles 2θ of approximately 8.47° (e.g., 8.47±0.2), approximately 9.37° (e.g., 9.37±0.2), approximately 10.51° (e.g., 10.51±0.2), approximately 13.98° (e.g., 13.98±0.2), approximately 16.20° (e.g., 16.20±0.2), approximately 17.26° (e.g., 17.26±0.2), approximately 23.70° (e.g., 23.70±0.2), approximately 24.01° (e.g., 24.01±0.2), approximately 24.43° (e.g., 24.43±0.2) and approximately 25.59° (e.g., 25.59±0.2); or (iii) Approximately 6.87° (e.g., 6.87±0.2), approximately 8.47° (e.g., 8.47±0.2), approximately 9.37° (e.g., 9.37±0.2), approximately 10.51° (e.g., 10.51±0.2), approximately 12.20° (e.g., 12.20±0.2), approximately 12.63° (e.g., 12.63±0.2), approximately 13.34° (e.g., 13.34±0.2), approximately 13.98° (e.g., 13.98±0.2), approximately 16.20° (e.g., 16.20±0.2), approximately 17.26° (e.g., 17.26±0.2), approximately 18.11° (e.g., For example, peaks at angles 2θ of 18.11±0.2), approximately 18.72° (for example, 18.72±0.2), approximately 19.42° (for example, 19.42±0.2), approximately 20.46° (for example, 20.46±0.2), approximately 21.87° (for example, 21.87±0.2), approximately 22.15° (for example, 22.15±0.2), approximately 23.70° (for example, 23.70±0.2), approximately 24.01° (for example, 24.01±0.2), approximately 24.43° (for example, 24.43±0.2), and approximately 25.59° (for example, 25.59±0.2); (b) Form II has an XRPD pattern substantially as shown in Figure 2A; (c) Form II has a DSC graph substantially as shown in Figure 2B; (d) Form II is characterized by having an endothermic peak at approximately 95.4°C, as measured by DSC; (e) Form II has a TGA graph substantially as shown in Figure 2B; and (f) Form II is characterized by exhibiting a weight loss of approximately 13.02% after heating from approximately 26.0°C to approximately 125.0°C, as measured by TGA.

[0059] Crystals of 1,5-naphthalenedisulfonate salt In one embodiment, the Spectrum provides a crystalline form (Form III) of the 1,5-naphthalenedisulfonate salt of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid.

[0060] In one embodiment, form III has an XRPD pattern substantially as shown in Figure 3A. Table 3 shows the peak positions and relative peak intensities that can be observed for the crystal using XRPD. [Table 4]

[0061] In one embodiment, form III has an XRPD pattern containing the peaks shown in Table 3. In one embodiment, form III has an XRPD pattern substantially shown in Figure 3A or as shown in Table 3, containing one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks having maximum intensity at angle 2θ. It should be understood that relative intensity and peak identification can vary due to many factors, including sample preparation, mounting, instruments and analytical methods and settings used to obtain the spectrum, temperature affecting the unit cell and the degree of solvation of the sample (e.g., degree of hydration). For example, relative peak intensity and peak identification can vary within the range of experimental error. In one embodiment, the identification of each peak listed herein can vary, for example, for form III, up to ±0.6°, ±0.4°, ±0.2°, or ±0.1°2θ. In one embodiment, the identification of each peak described herein may vary independently up to ±0.2°2θ for, for example, morphology III.

[0062] In one embodiment, form III has an XRPD pattern including peaks identified at angles 2θ(°) as listed in Table 3, and each of these peaks may vary independently in its identification at angles 2θ(°) as described herein. For example, form III may be approximately 3.17° (e.g., 3.17±0.2), approximately 12.58° (e.g., 12.58±0.2), approximately 15.87° (e.g., 15.87±0.2), approximately 16.77° (e.g., 16.77±0.2), approximately 18.78° (e.g., 18.78±0.2), approximately 23.85° (e.g., 23.85±0.2), and approximately 25.30° (e.g., 25 The XRPD pattern may have peaks identified at angles 2θ(°) of approximately 0.30±0.2, 27.34° (e.g., 27.34±0.2), 29.61° (e.g., 29.61±0.2), 31.95° (e.g., 31.95±0.2), 38.05° (e.g., 38.05±0.2), and 38.63° (e.g., 38.63±0.2). In one embodiment, form III has one or more peaks (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine or at least ten) identified at angles 2θ(°): approximately 3.17 (e.g., 3.17 ± 0.2), approximately 12.58 (e.g., 12.58 ± 0.2), approximately 15.87 (e.g., 15.87 ± 0.2), approximately 16.77 (e.g., It has an XRPD pattern including 16.77±0.2), approximately 18.78 (e.g., 18.78±0.2), approximately 23.85 (e.g., 23.85±0.2), approximately 25.30 (e.g., 25.30±0.2), approximately 27.34 (e.g., 27.34±0.2), approximately 29.61 (e.g., 29.61±0.2), approximately 31.95 (e.g., 31.95±0.2), approximately 38.05 (e.g., 38.05±0.2), and approximately 38.63 (e.g., 38.63±0.2).In one embodiment, form III has an XRPD pattern that includes peaks identified at angles 2θ(°) of approximately 12.58 (e.g., 12.58±0.2), approximately 15.87 (e.g., 15.87±0.2), approximately 16.77 (e.g., 16.77±0.2), approximately 23.85 (e.g., 23.85±0.2), and approximately 31.95 (e.g., 31.95±0.2). In one embodiment, form III has an XRPD pattern including one or more peaks (e.g., at least one, at least two, at least three, at least four, or at least five) identified at angles 2θ(°): approximately 12.58 (e.g., 12.58±0.2), approximately 15.87 (e.g., 15.87±0.2), approximately 16.77 (e.g., 16.77±0.2), approximately 23.85 (e.g., 23.85±0.2), and approximately 31.95 (e.g., 31.95±0.2). In one embodiment, form III has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 15.87 (e.g., 15.87±0.2) and approximately 23.85 (e.g., 23.85±0.2). In one embodiment, form III has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 12.58, approximately 15.87, approximately 16.77, and approximately 23.85. In one embodiment, form III has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 12.58±0.2, approximately 15.87±0.2, approximately 16.77±0.2, and approximately 23.85±0.2. In one embodiment, form III has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 12.58, approximately 15.87, and approximately 16.77. In one embodiment, form III has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 12.58±0.2, approximately 15.87±0.2, and approximately 16.77±0.2. In one embodiment, form III has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 12.58, approximately 15.87, and approximately 23.85. In another embodiment, form III has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 12.58±0.2, approximately 15.87±0.2, and approximately 23.85±0.2.In one embodiment, form III has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 12.58 and approximately 15.87. In one embodiment, form III has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 12.58±0.2 and approximately 15.87±0.2. In one embodiment, form III has an XRPD pattern including a peak identified at angle 2θ(°) of approximately 12.58. In one embodiment, form III has an XRPD pattern including a peak identified at angle 2θ(°) of approximately 12.58±0.2.

[0063] In one embodiment, form III has a DSC graph substantially as shown in Figure 3B. In one embodiment, form III is characterized by having an endothermic peak at approximately 103.4°C.

[0064] In one embodiment, form III has a TGA graph substantially as shown in Figure 3B. In one embodiment, form III has a TGA graph substantially as shown in Figure 1B. In one embodiment, form III is characterized by exhibiting a weight loss of about 11.11% after heating from about 23.0°C to about 150.0°C, as measured by TGA.

[0065] In one embodiment of Form III, at least one, at least two, at least three, at least four, at least five, or all of the following (a) to (f) apply: (a) Form III has an XRPD pattern that includes the following peaks: (i) Peaks at angles 2θ of approximately 15.87° (e.g., 15.87 ± 0.2) and approximately 23.85° (e.g., 23.85 ± 0.2); (ii) Peaks at angles 2θ of approximately 12.58° (e.g., 12.58±0.2), approximately 15.87° (e.g., 15.87±0.2), approximately 16.77° (e.g., 16.77±0.2), approximately 23.85° (e.g., 23.85±0.2), and approximately 31.95° (e.g., 31.95±0.2); or (iii) Approximately 3.17° (e.g., 3.17±0.2), approximately 12.58° (e.g., 12.58±0.2), approximately 15.87° (e.g., 15.87±0.2), approximately 16.77° (e.g., 16.77±0.2), approximately 18.78° (e.g., 18.78±0.2), approximately 23.85° (e.g., 23.85±0.2), approximately 25.30° Peaks at angles 2θ of approximately 25.30±0.2, 27.34° (e.g., 27.34±0.2), 29.61° (e.g., 29.61±0.2), 31.95° (e.g., 31.95±0.2), 38.05° (e.g., 38.05±0.2), and 38.63° (e.g., 38.63±0.2); (b) Form III has an XRPD pattern substantially as shown in Figure 3A; (c) Form III has a DSC graph substantially as shown in Figure 3B; (d) Form III is characterized by having an endothermic peak of approximately 103.4°C, as measured by DSC; (e) Form III has a TGA graph substantially as shown in Figure 3B; and (f) Form III is characterized by exhibiting a weight loss of approximately 11.11% after heating from approximately 23.0°C to approximately 150.0°C, as measured by TGA.

[0066] Crystals of phosphate solvates In one embodiment, the present invention provides a crystalline (Form IV) mixed solvate of isopropyl alcohol and water of the phosphate of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid.

[0067] In one embodiment, form IV has an XRPD pattern substantially as shown in Figure 4. Table 4 shows the peak positions and relative peak intensities that can be observed for the crystal using XRPD. [Table 5] [Table 6]

[0068] In one embodiment, morphology IV has an XRPD pattern containing the peaks shown in Table 4. In one embodiment, morphology IV has an XRPD pattern substantially shown in Figure 4 or as shown in Table 4, containing one or more (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten) peaks having maximum intensity at angle 2θ. It should be understood that relative intensity and peak identification can vary due to many factors, including sample preparation, mounting, instruments and analytical methods and settings used to obtain the spectrum, temperature affecting the unit cell and the degree of solvation of the sample (e.g., degree of hydration). For example, relative peak intensity and peak identification can vary within the range of experimental error. In one embodiment, the identification of each peak listed herein can vary independently, for example, for morphology IV, up to ±0.6°, ±0.4°, ±0.2°, or ±0.1°2θ. In one embodiment, the identification of each peak described herein may vary independently up to ±0.2°2θ for, for example, morphology IV.

[0069] In one embodiment, form IV has an XRPD pattern including peaks identified at angles 2θ(°) as listed in Table 4, and each of these peaks may independently vary in its identification at angles 2θ(°) as described herein. For example, form IV may be approximately 4.14 (e.g., 4.14±0.2), approximately 20.02 (e.g., 20.02±0.2), approximately 21.57 (e.g., 21.57±0.2), approximately 6.64 (e.g., 6.64±0.2), approximately 25.22 (e.g., 25.22±0.2), approximately 15.18 (e.g., 15.18±0.2), approximately 21.79 (e.g., 21.79±0.2), approximately 11.20 (e.g., 11.2 0±0.2), approximately 11.65 (e.g., 11.65±0.2), approximately 24.86 (e.g., 24.86±0.2), approximately 17.18 (e.g., 17.18±0.2), approximately 19.17 (e.g., 19.17±0.2), approximately 23.42 (e.g., 23.42±0.2), approximately 20.39 (e.g., 20.39±0.2), approximately 16.69 (e.g., 16.69±0.2), approximately 25.03 (e.g., 25. 0.3±0.2), approximately 9.78 (e.g., 9.78±0.2), approximately 22.89 (e.g., 22.89±0.2), approximately 23.62 (e.g., 23.62±0.2), approximately 12.53 (e.g., 12.53±0.2), approximately 23.96 (e.g., 23.96±0.2), approximately 20.76 (e.g., 20.76±0.2), approximately 14.60 (e.g., 14.60±0.2), approximately 22.16 (e.g., 22.1 The XRPD pattern may have peaks identified at angles 2θ(°) of approximately 6±0.2), 21.31 (e.g., 21.31±0.2), 28.25 (e.g., 28.25±0.2), 17.71 (e.g., 17.71±0.2), 12.43 (e.g., 12.43±0.2), 26.72 (e.g., 26.72±0.2), and 33.66 (e.g., 33.66±0.2), respectively.In one embodiment, form IV has one or more peaks (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine or at least ten) identified at angles 2θ(°): approximately 4.14 (e.g., 4.14 ± 0.2), approximately 20.02 (e.g., 20.02 ± 0.2), approximately 21.57 (e.g., 21.57 ± 0.2), approximately 6.64 (e.g. For example, 6.64±0.2), approximately 25.22 (for example, 25.22±0.2), approximately 15.18 (for example, 15.18±0.2), approximately 21.79 (for example, 21.79±0.2), approximately 11.20 (for example, 11.20±0.2), approximately 11.65 (for example, 11.65±0.2), approximately 24.86 (for example, 24.86±0.2), approximately 17.18 (for example, 17.18±0.2), approximately 19.17 (for example, 19.17±0.2), approximately 23.42 (for example, 2 3.42±0.2), approximately 20.39 (e.g., 20.39±0.2), approximately 16.69 (e.g., 16.69±0.2), approximately 25.03 (e.g., 25.03±0.2), approximately 9.78 (e.g., 9.78±0.2), approximately 22.89 (e.g., 22.89±0.2), approximately 23.62 (e.g., 23.62±0.2), approximately 12.53 (e.g., 12.53±0.2), approximately 23.96 (e.g., 23.96±0.2), approximately 20.76 (e.g., 20.7 It has an XRPD pattern including 6±0.2), approximately 14.60 (e.g., 14.60±0.2), approximately 22.16 (e.g., 22.16±0.2), approximately 21.31 (e.g., 21.31±0.2), approximately 28.25 (e.g., 28.25±0.2), approximately 17.71 (e.g., 17.71±0.2), approximately 12.43 (e.g., 12.43±0.2), approximately 26.72 (e.g., 26.72±0.2), and approximately 33.66 (e.g., 33.66±0.2).In one embodiment, form IV may have an XRPD pattern containing peaks identified at angles 2θ(°) of approximately 4.14 (e.g., 4.14±0.2), approximately 20.02 (e.g., 20.02±0.2), approximately 21.57 (e.g., 21.57±0.2), approximately 6.64 (e.g., 6.64±0.2), approximately 25.22 (e.g., 25.22±0.2), approximately 15.18 (e.g., 15.18±0.2), approximately 21.79 (e.g., 21.79±0.2), approximately 11.20 (e.g., 11.20±0.2), approximately 11.65 (e.g., 11.65±0.2), and approximately 24.86 (e.g., 24.86±0.2). In one embodiment, form IV has one or more peaks (e.g., at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine or at least ten) identified at angles 2θ(°): approximately 4.14 (e.g., 4.14 ± 0.2), approximately 20.02 (e.g., 20.02 ± 0.2), approximately 21.57 (e.g., It has an XRPD pattern including 21.57±0.2), approximately 6.64 (e.g., 6.64±0.2), approximately 25.22 (e.g., 25.22±0.2), approximately 15.18 (e.g., 15.18±0.2), approximately 21.79 (e.g., 21.79±0.2), approximately 11.20 (e.g., 11.20±0.2), approximately 11.65 (e.g., 11.65±0.2), and approximately 24.86 (e.g., 24.86±0.2). In one embodiment, form IV has an XRPD pattern that includes peaks identified at angles 2θ(°) of approximately 4.14 (e.g., 4.14±0.2), approximately 20.02 (e.g., 20.02±0.2), approximately 21.57 (e.g., 21.57±0.2), approximately 6.64 (e.g., 6.64±0.2), and approximately 25.22 (e.g., 25.22±0.2). In one embodiment, form IV has an XRPD pattern containing one or more (e.g., at least one, at least two, at least three, at least four, or at least five) peaks identified at angles 2θ(°) of approximately 4.14 (e.g., 4.14 ± 0.2), approximately 20.02 (e.g., 20.02 ± 0.2), approximately 21.57 (e.g., 21.57 ± 0.2), approximately 6.64 (e.g., 6.64 ± 0.2), and approximately 25.22 (e.g., 25.22 ± 0.2).In one embodiment, morphology IV has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.14, approximately 6.64, approximately 11.20, and approximately 15.18. In one embodiment, morphology IV has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.14±0.2, approximately 6.64±0.2, approximately 11.20±0.2, and approximately 15.18±0.2. In one embodiment, morphology IV has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.14, approximately 6.64, and approximately 11.20. In one embodiment, morphology IV has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.14±0.2, approximately 6.64±0.2, and approximately 11.20±0.2. In one embodiment, morphology IV has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.14, approximately 6.64, and approximately 15.18. In one embodiment, morphology IV has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.14±0.2, approximately 6.64±0.2, and approximately 15.18±0.2. In one embodiment, morphology IV has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.14 and approximately 6.64. In one embodiment, morphology IV has an XRPD pattern including peaks identified at angles 2θ(°) of approximately 4.14±0.2 and approximately 6.64±0.2. In one embodiment, morphology IV has an XRPD pattern including a peak identified at angle 2θ(°) of approximately 4.14. In one embodiment, morphology IV has an XRPD pattern including a peak identified at angle 2θ(°) of approximately 4.14±0.2.

[0070] In some embodiments of the crystalline materials disclosed herein (e.g., Form I, Form II, Form III, or IV), the crystalline material is substantially anhydrous. For example, in some embodiments, the crystalline material has a water content of about 1%, about 0.5%, or less than about 0.1% by weight. In some embodiments, the crystalline material has a water content (by weight) in the range of one of about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, or about 10, or between any two of the above values. For example, the crystalline material may have a water content of about 1 to 10% by weight. The water content may be about 2 to 10% by weight. The water content may be about 3 to 10% by weight. The water content may be about 4 to 10% by weight. The water content may be about 5 to 10% by weight. The moisture content can be approximately 6-10% by weight. The moisture content can be approximately 7-10% by weight. The moisture content can be approximately 8-10% by weight. The moisture content can be approximately 9-10% by weight. The moisture content can be approximately 1-9% by weight. The moisture content can be approximately 2-9% by weight. The moisture content can be approximately 3-9% by weight. The moisture content can be approximately 4-9% by weight. The moisture content can be approximately 5-9% by weight. The moisture content can be approximately 6-9% by weight. The moisture content can be approximately 7-9% by weight. The moisture content can be approximately 8-9% by weight. The moisture content can be approximately 1-8% by weight. The moisture content can be approximately 2-8% by weight. The moisture content can be approximately 3-8% by weight. The moisture content can be approximately 4-8% by weight. The moisture content can be approximately 5-8% by weight. The moisture content can be approximately 6-8% by weight. The moisture content can be approximately 7-8% by weight. The moisture content can be approximately 1-7% by weight. The moisture content can be approximately 2-7% by weight. The moisture content can be approximately 3-7% by weight. The moisture content can be approximately 4-7% by weight. The moisture content can be approximately 5-7% by weight. The moisture content can be approximately 6-7% by weight. The moisture content can be approximately 1-6% by weight. The moisture content can be approximately 2-6% by weight. The moisture content can be approximately 3-6% by weight. The moisture content can be approximately 4-6% by weight. The moisture content can be approximately 5-6% by weight. The moisture content can be approximately 1-5% by weight. The moisture content can be approximately 2-5% by weight. The moisture content can be approximately 3-5% by weight.The moisture content may be approximately 4-5% by weight. The moisture content may be approximately 1-4% by weight. The moisture content may be approximately 2-4% by weight. The moisture content may be approximately 3-4% by weight. The crystal may have a moisture content that varies within ±1, ±0.75, ±0.5, ±0.25, or ±0.1% by weight of one of the following weight percent values: 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10. For example, the crystal may have a moisture content of approximately 1 ± 0.75% by weight. The moisture content may be approximately 1 ± 0.5% by weight. The moisture content may be approximately 1 ± 0.25% by weight. The moisture content may be approximately 1 ± 0.1% by weight. The moisture content may be approximately 1.5 ± 1% by weight. The moisture content may be approximately 1.5 ± 0.75% by weight. The moisture content may be approximately 1.5 ± 0.5% by weight. The moisture content may be approximately 1.5 ± 0.25% by weight. The moisture content may be approximately 1.5 ± 0.1% by weight. The moisture content may be approximately 2 ± 1% by weight. The moisture content may be approximately 2 ± 0.75% by weight. The moisture content may be approximately 2 ± 0.5% by weight. The moisture content may be approximately 2 ± 0.25% by weight. The moisture content may be approximately 2 ± 0.1% by weight. The moisture content may be approximately 2.5 ± 1% by weight. The moisture content may be approximately 2.5 ± 0.75% by weight. The moisture content may be approximately 2.5 ± 0.5% by weight. The moisture content may be approximately 2.5 ± 0.25% by weight. The moisture content may be approximately 2.5 ± 0.1% by weight. The moisture content may be approximately 3 ± 1% by weight. The moisture content may be approximately 3 ± 0.75% by weight. The moisture content may be approximately 3 ± 0.5% by weight. The moisture content may be approximately 3 ± 0.25% by weight. The moisture content may be approximately 3 ± 0.1% by weight. The moisture content may be approximately 3.5 ± 1% by weight. The moisture content may be approximately 3.5 ± 0.75% by weight. The moisture content may be approximately 3.5 ± 0.5% by weight. The moisture content may be approximately 3.5 ± 0.25% by weight. The moisture content may be approximately 3.5 ± 0.1% by weight. The moisture content may be approximately 4 ± 1% by weight. The moisture content may be approximately 4 ± 0.75% by weight. The moisture content may be approximately 4 ± 0.5% by weight. The moisture content may be approximately 4 ± 0.25% by weight. The moisture content may be approximately 4 ± 0.1% by weight. The moisture content may be approximately 4.5 ± 1% by weight. The moisture content may be approximately 4.5 ± 0.75% by weight.The moisture content may be approximately 4.5 ± 0.5% by weight. The moisture content may be approximately 4.5 ± 0.25% by weight. The moisture content may be approximately 4.5 ± 0.1% by weight. The moisture content may be approximately 5 ± 1% by weight. The moisture content may be approximately 5 ± 0.75% by weight. The moisture content may be approximately 5 ± 0.5% by weight. The moisture content may be approximately 5 ± 0.25% by weight. The moisture content may be approximately 5 ± 0.1% by weight. The moisture content may be approximately 5.5 ± 1% by weight. The moisture content may be approximately 5.5 ± 0.75% by weight. The moisture content may be approximately 5.5 ± 0.5% by weight. The moisture content may be approximately 5.5 ± 0.25% by weight. The moisture content may be approximately 5.5 ± 0.1% by weight. The moisture content may be approximately 6 ± 1% by weight. The moisture content may be approximately 6 ± 0.5% by weight. The moisture content may be approximately 6.5 ± 1% by weight. The moisture content may be approximately 6.5 ± 0.5% by weight. The moisture content may be approximately 7 ± 1% by weight. The moisture content may be approximately 7 ± 0.5% by weight. The moisture content may be approximately 7.5 ± 1% by weight. The moisture content may be approximately 7.5 ± 0.5% by weight. The moisture content may be approximately 8 ± 1% by weight. The moisture content may be approximately 8 ± 0.5% by weight. The moisture content may be approximately 8.5 ± 1% by weight. The moisture content may be approximately 8.5 ± 0.5% by weight. The moisture content may be approximately 9 ± 1% by weight. The moisture content may be approximately 9 ± 0.5% by weight. The moisture content may be approximately 9.5 ± 0.5% by weight. The moisture content may be approximately 9.5 ± 0.25% by weight.

[0071] Manufacturing method Form I In one embodiment, the present invention provides a method for producing Form I, comprising the step of preparing a mixture of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid and phosphoric acid in a solvent. In one embodiment, the mixture is prepared as a slurry. In one embodiment, the solvent comprises an alcohol. In one embodiment, the solvent comprises ethanol. In one embodiment, the molar ratio of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid to phosphoric acid is about 1:1. In one embodiment, the method is carried out at room temperature. In one embodiment, the method for producing Form I further includes subjecting the mixture to one or more (e.g., 1, 2, 3, 4, or 5 or more) temperature cycles (e.g., each cycle being from 50°C to 5°C at 0.05°C / min, and then from 5°C to 50°C at 0.375°C / min). In one embodiment, each temperature cycle includes decreasing the temperature from about 50°C to about 5°C, and increasing the temperature from about 5°C to about 50°C at about 0.375°C / min.

[0072] In one embodiment, a method is provided for producing form I, comprising the step of converting the zwitterion (ZI) of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid to form I. In one embodiment, the step of converting (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid ZI to form I comprises the step of mixing (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid ZI and phosphoric acid in a solvent. In one embodiment, the solvent comprises an alcohol. In one embodiment, the solvent comprises a 1:4 methanol / ethanol (v / v) mixture. In one embodiment, the step of mixing (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoate ZI and phosphoric acid comprises the following steps: (a1) mixing (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoate ZI with phosphoric acid (about 0.25 equivalent); (b1) adding a seed crystal of form I; and (c1) adding phosphoric acid (about 0.8 equivalent) to the mixture of step (b1). In one embodiment, the mixture from step (c1) is stored at approximately 30°C for approximately 2 hours, and then at approximately 20°C for approximately 2 hours. In one embodiment, the method for producing form I further comprises the step of converting the hydrochloride of benzyl(S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthiridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoate ZI.In one embodiment, the hydrochloride salt is a dihydrochloride salt. In one embodiment, the step of converting the hydrochloride salt of benzyl(S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoate ZI includes the following steps: (a2) dissolving the hydrochloride salt of benzyl(S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoate in a concentrated hydrochloric acid solution; and (b2) A step of adjusting the pH of the mixture in step (a2) to 7.2 to 7.6. In one embodiment, the step of adjusting the pH of the mixture in step (a2) includes adding NaOH and / or NaHCO3 to the mixture in step (a2). In one embodiment, the step of converting the hydrochloride of benzyl(S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoate ZI further includes extracting ZI using an organic solvent. In one embodiment, the organic solvent is DCM.

[0073] Form II In one embodiment, a method is provided for producing Form II, comprising the step of preparing a mixture of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid and fumaric acid in a solvent. In one embodiment, the mixture is prepared as a slurry. In one embodiment, the solvent comprises a ketone (e.g., acetone), water, or a mixture thereof. In one embodiment, the solvent comprises a mixture of acetone and water. In one embodiment, the acetone:water ratio is about 19:1 (v / v). In one embodiment, the method for producing Form II further comprises subjecting the mixture to one or more (e.g., 1, 2, 3, 4, or 5 or more) temperature cycles (e.g., each cycle being from 50°C to 5°C at 0.05°C / min, then from 5°C to 50°C at 0.375°C / min). In one embodiment, each temperature cycle includes decreasing the temperature from about 50°C to about 5°C at a rate of about 0.375°C / min, and increasing the temperature from about 5°C to about 50°C.

[0074] Form III In one embodiment, a method is provided for producing Form III, comprising the step of preparing a mixture of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid and 1,5-naphthalenedisulfonic acid in a solvent. In one embodiment, the mixture is prepared as a slurry. In one embodiment, the solvent comprises an acetate (e.g., isopropyl acetate or ethyl acetate). In one embodiment, the solvent comprises ethyl acetate. In one embodiment, the method is carried out at room temperature.

[0075] Form IV In one embodiment, a method is provided for producing Form IV, comprising the step of preparing a mixture of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid and phosphoric acid (for example, in a 1:1 molar ratio) in a solvent containing isopropyl alcohol. In one embodiment, the solvent contains water that is effective in allowing Form IV to incorporate water. In one embodiment, the solvent contains methanol. In one embodiment, the method is carried out in ambient air containing water that is effective in allowing Form IV to incorporate water from the ambient air. In one embodiment, the method is carried out at room temperature.

[0076] In one embodiment of a method for producing a crystalline material disclosed herein (e.g., Form I, Form II, Form III, or IV), the method further includes producing the crystalline material such that it is substantially anhydrous (e.g., drying). For example, in one embodiment, the method further includes producing the crystalline material such that it has a moisture content of less than about 1% by weight, less than about 0.5% by weight, or less than about 0.1% by weight. In one embodiment, the method further includes producing the crystalline material such that it has a moisture content (by weight) in the range of about 1, about 1.5, about 2, about 2.5, about 3, about 3.5, about 4, about 4.5, about 5, about 5.5, about 6, about 6.5, about 7, about 7.5, about 8, about 8.5, about 9, about 9.5, or about 10, or between any two of the above values. In some embodiments, the method includes a humidification step. For example, the crystalline material may have a moisture content of about 1 to 10% by weight. The moisture content may be about 2 to 10% by weight. The moisture content can be approximately 3-10% by weight. The moisture content can be approximately 4-10% by weight. The moisture content can be approximately 5-10% by weight. The moisture content can be approximately 6-10% by weight. The moisture content can be approximately 7-10% by weight. The moisture content can be approximately 8-10% by weight. The moisture content can be approximately 9-10% by weight. The moisture content can be approximately 1-9% by weight. The moisture content can be approximately 2-9% by weight. The moisture content can be approximately 3-9% by weight. The moisture content can be approximately 4-9% by weight. The moisture content can be approximately 5-9% by weight. The moisture content can be approximately 6-9% by weight. The moisture content can be approximately 7-9% by weight. The moisture content can be approximately 8-9% by weight. The moisture content can be approximately 1-8% by weight. The moisture content can be approximately 2-8% by weight. The moisture content can be approximately 3-8% by weight. The moisture content can be approximately 4-8% by weight. The moisture content can be approximately 5-8% by weight. The moisture content can be approximately 6-8% by weight. The moisture content can be approximately 7-8% by weight. The moisture content can be approximately 1-7% by weight. The moisture content can be approximately 2-7% by weight. The moisture content can be approximately 3-7% by weight. The moisture content can be approximately 4-7% by weight. The moisture content can be approximately 5-7% by weight. The moisture content can be approximately 6-7% by weight. The moisture content can be approximately 1-6% by weight. The moisture content can be approximately 2-6% by weight.The moisture content may be approximately 3-6% by weight. The moisture content may be approximately 4-6% by weight. The moisture content may be approximately 5-6% by weight. The moisture content may be approximately 1-5% by weight. The moisture content may be approximately 2-5% by weight. The moisture content may be approximately 3-5% by weight. The moisture content may be approximately 4-5% by weight. The moisture content may be approximately 1-4% by weight. The moisture content may be approximately 2-4% by weight. The moisture content may be approximately 3-4% by weight. This crystal may have a moisture content that varies by weight of ±1, ±0.75, ±0.5, ±0.25, or ±0.1% around one of the weight percent values ​​of 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10. For example, the crystal may have a water content of approximately 1 ± 0.75% by weight. The water content may be approximately 1 ± 0.5% by weight. The water content may be approximately 1 ± 0.25% by weight. The water content may be approximately 1 ± 0.1% by weight. The water content may be approximately 1.5 ± 1% by weight. The water content may be approximately 1.5 ± 0.75% by weight. The water content may be approximately 1.5 ± 0.5% by weight. The water content may be approximately 1.5 ± 0.25% by weight. The water content may be approximately 1.5 ± 0.1% by weight. The water content may be approximately 2 ± 1% by weight. The water content may be approximately 2 ± 0.75% by weight. The water content may be approximately 2 ± 0.5% by weight. The water content may be approximately 2 ± 0.25% by weight. The water content may be approximately 2 ± 0.1% by weight. The water content may be approximately 2.5 ± 1% by weight. The moisture content may be approximately 2.5 ± 0.75% by weight. The moisture content may be approximately 2.5 ± 0.5% by weight. The moisture content may be approximately 2.5 ± 0.25% by weight. The moisture content may be approximately 2.5 ± 0.1% by weight. The moisture content may be approximately 3 ± 1% by weight. The moisture content may be approximately 3 ± 0.75% by weight. The moisture content may be approximately 3 ± 0.5% by weight. The moisture content may be approximately 3 ± 0.25% by weight. The moisture content may be approximately 3 ± 0.1% by weight. The moisture content may be approximately 3.5 ± 1% by weight. The moisture content may be approximately 3.5 ± 0.75% by weight. The moisture content may be approximately 3.5 ± 0.5% by weight. The moisture content may be approximately 3.5 ± 0.25% by weight. The moisture content may be approximately 3.5 ± 0.1% by weight. The moisture content may be approximately 4 ± 1% by weight. The moisture content may be approximately 4 ± 0.75% by weight.The moisture content may be approximately 4 ± 0.5% by weight. The moisture content may be approximately 4 ± 0.25% by weight. The moisture content may be approximately 4 ± 0.1% by weight. The moisture content may be approximately 4.5 ± 1% by weight. The moisture content may be approximately 4.5 ± 0.75% by weight. The moisture content may be approximately 4.5 ± 0.5% by weight. The moisture content may be approximately 4.5 ± 0.25% by weight. The moisture content may be approximately 4.5 ± 0.1% by weight. The moisture content may be approximately 5 ± 1% by weight. The moisture content may be approximately 5 ± 0.75% by weight. The moisture content may be approximately 5 ± 0.5% by weight. The moisture content may be approximately 5 ± 0.25% by weight. The moisture content may be approximately 5 ± 0.1% by weight. The moisture content may be approximately 5.5 ± 1% by weight. The moisture content may be approximately 5.5 ± 0.75% by weight. The moisture content may be approximately 5.5 ± 0.5% by weight. The moisture content may be approximately 5.5 ± 0.25% by weight. The moisture content may be approximately 5.5 ± 0.1% by weight. The moisture content may be approximately 6 ± 1% by weight. The moisture content may be approximately 6 ± 0.5% by weight. The moisture content may be approximately 6.5 ± 1% by weight. The moisture content may be approximately 6.5 ± 0.5% by weight. The moisture content may be approximately 7 ± 1% by weight. The moisture content may be approximately 7 ± 0.5% by weight. The moisture content may be approximately 7.5 ± 1% by weight. The moisture content may be approximately 7.5 ± 0.5% by weight. The moisture content may be approximately 8 ± 1% by weight. The moisture content may be approximately 8 ± 0.5% by weight. The moisture content may be approximately 8.5 ± 0.5% by weight. The moisture content may be approximately 9 ± 1% by weight. The moisture content may be approximately 9 ± 0.5% by weight. The moisture content may be approximately 9.5 ± 0.5% by weight. The moisture content may be approximately 9.5 ± 0.25% by weight.

[0077] Pharmaceutical compositions and dosage forms A pharmaceutical composition comprising any of the crystalline materials detailed herein, for example, Form I, Form II, Form III, or Form IV, is encompassed by the present invention. Accordingly, the present invention includes a pharmaceutical composition comprising a crystalline material disclosed herein (for example, Form I, Form II, Form III, or Form IV) and a pharmaceutically acceptable carrier or excipient. In one embodiment, the pharmaceutical composition is a composition for controlled release of any of the crystalline materials detailed herein.

[0078] In one embodiment, a composition comprising form I is provided. In one embodiment, the composition is substantially free of amorphous or noncrystalline (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid or a salt thereof. In some embodiments of a composition containing Form I, Form I constitutes at least about 0.1% by weight, at least about 0.3% by weight, at least about 0.5% by weight, at least about 0.8% by weight, at least about 1.0% by weight, at least about 5.0% by weight, at least about 10% by weight, at least about 20% by weight, at least about 30% by weight, at least about 40% by weight, at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 96% by weight, at least about 97% by weight, at least about 98% by weight, at least about 99% by weight, or at least 99.9% by weight of the total composition. In some embodiments of compositions comprising Form I, at least about 0.1% by weight, at least about 0.3% by weight, at least about 0.5% by weight, at least about 0.8% by weight, at least about 1.0% by weight, at least about 5.0% by weight, at least about 10% by weight, at least about 20% by weight, at least about 30% by weight, at least about 40% by weight, at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 96% by weight, at least about 97% by weight, at least about 98% by weight, at least about 99% by weight, or at least 99.9% by weight of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid is present in Form I.

[0079] In one embodiment, a composition comprising form II is provided. In one embodiment, the composition substantially does not contain amorphous or noncrystalline (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid or a salt thereof. In some embodiments of a composition comprising Form II, Form II constitutes at least about 0.1% by weight, at least about 0.3% by weight, at least about 0.5% by weight, at least about 0.8% by weight, at least about 1.0% by weight, at least about 5.0% by weight, at least about 10% by weight, at least about 20% by weight, at least about 30% by weight, at least about 40% by weight, at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 96% by weight, at least about 97% by weight, at least about 98% by weight, at least about 99% by weight, or at least 99.9% by weight of the total composition. In some embodiments of compositions comprising Form II, at least about 0.1% by weight, at least about 0.3% by weight, at least about 0.5% by weight, at least about 0.8% by weight, at least about 1.0% by weight, at least about 5.0% by weight, at least about 10% by weight, at least about 20% by weight, at least about 30% by weight, at least about 40% by weight, at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 96% by weight, at least about 97% by weight, at least about 98% by weight, at least about 99% by weight, or at least 99.9% by weight of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid is present in Form II.

[0080] In one embodiment, a composition comprising form III is provided. In one embodiment, the composition is substantially free of amorphous or noncrystalline (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid or a salt thereof. In some embodiments of a composition comprising Form III, Form III constitutes at least about 0.1% by weight, at least about 0.3% by weight, at least about 0.5% by weight, at least about 0.8% by weight, at least about 1.0% by weight, at least about 5.0% by weight, at least about 10% by weight, at least about 20% by weight, at least about 30% by weight, at least about 40% by weight, at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 96% by weight, at least about 97% by weight, at least about 98% by weight, at least about 99% by weight, or at least 99.9% by weight of the total composition. In some embodiments of compositions containing Form III, at least about 0.1% by weight, at least about 0.3% by weight, at least about 0.5% by weight, at least about 0.8% by weight, at least about 1.0% by weight, at least about 5.0% by weight, at least about 10% by weight, at least about 20% by weight, at least about 30% by weight, at least about 40% by weight, at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 96% by weight, at least about 97% by weight, at least about 98% by weight, at least about 99% by weight, or at least 99.9% by weight of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid is present in Form III.

[0081] In one embodiment, a composition comprising form IV is provided. In one embodiment, the composition is substantially free of amorphous or noncrystalline (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid or a salt thereof. In some embodiments of a composition comprising Form IV, Form IV is at least about 0.1% by weight, at least about 0.3% by weight, at least about 0.5% by weight, at least about 0.8% by weight, at least about 1.0% by weight, at least about 5.0% by weight, at least about 10% by weight, at least about 20% by weight, at least about 30% by weight, at least about 40% by weight, at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 96% by weight, at least about 97% by weight, at least about 98% by weight, at least about 99% by weight, or at least 99.9% by weight of the total composition. In some embodiments of compositions comprising Form IV, at least about 0.1% by weight, at least about 0.3% by weight, at least about 0.5% by weight, at least about 0.8% by weight, at least about 1.0% by weight, at least about 5.0% by weight, at least about 10% by weight, at least about 20% by weight, at least about 30% by weight, at least about 40% by weight, at least about 50% by weight, at least about 60% by weight, at least about 70% by weight, at least about 80% by weight, at least about 85% by weight, at least about 90% by weight, at least about 95% by weight, at least about 96% by weight, at least about 97% by weight, at least about 98% by weight, at least about 99% by weight, or at least 99.9% by weight of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid is present in Form IV.

[0082] The crystalline or composition disclosed herein may be formulated for any available delivery route, including oral, mucosal (e.g., intranasal, sublingual, vaginal, buccal, or rectal), parenteral (e.g., intramuscular, subcutaneous, or intravenous), topical or transdermal delivery forms, or forms suitable for inhalation. The crystalline or composition disclosed herein may be formulated with suitable carriers to provide delivery forms, including but not limited to tablets, caplets, capsules (e.g., hard gelatin capsules or soft gelatin capsules), cachets, lozenges, gums, dispersants, suppositories, ointments, poultices, pastes, powders, bandages, creams, solutions, patches, aerosols (e.g., nasal sprays or inhalants), gels, suspensions (e.g., aqueous or non-aqueous liquid suspensions, oil-in-water emulsions, or water-in-oil liquid emulsions), solutions, and elixirs.

[0083] The crystalline compounds disclosed herein can be used in the manufacture of pharmaceutical formulations, etc., by combining the crystalline compounds as an active ingredient with a pharmaceutically acceptable carrier, such as those described above. Depending on the therapeutic dosage form of the system (e.g., transdermal patch versus oral tablet), the carrier may be in various forms. Furthermore, the pharmaceutical formulation may contain preservatives, solubilizers, stabilizers, re-wetting agents, emulsifiers, sweeteners, colorants, modifiers, and salts, buffers, coatings, or antioxidants for adjusting osmotic pressure. Formulations containing the compound may also contain other substances having useful therapeutic properties. Pharmaceutical formulations can be manufactured by known pharmaceutical methods. Suitable formulations are, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, 21 st This can be seen in the ed. (2005), which is incorporated herein by reference.

[0084] The crystalline compounds disclosed herein can be administered to an individual (e.g., a human) in the form of commonly accepted oral compositions such as tablets, coated tablets, and hard or soft-shell gel capsules, emulsions, or suspensions. Examples of carriers that can be used in the manufacture of such compositions include lactose, corn starch or its derivatives, talc, stearate or its salts. Acceptable carriers for gel capsules, including soft-shells, include, for example, vegetable oils, waxes, fats, semi-solid and liquid polyols. Furthermore, pharmaceutical formulations may contain preservatives, solubilizers, stabilizers, re-wetters, emulsifiers, sweeteners, colorants, modifiers, and salts for osmotic pressure adjustment, buffers, coatings, or antioxidants.

[0085] The crystalline material disclosed herein can be incorporated into tablets in any dosage form described herein, for example, the crystalline material can be incorporated into 10 mg tablets. Examples of dosages of the crystalline material disclosed herein are disclosed in U.S. Patent Application No. 16 / 843,824, U.S. Publication No. 2020-0352942.

[0086] In various embodiments, the dosage, for example, the unit dose for daily administration, is 1, 2.5, 5, 7.5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 140, 150, 160, 170, 175, 180, 190, 200, 225, 240, 250, 275, 300, 320, One of the following amounts: 325, 350, 375, 400, 425, 450, 475, 480, 500, 525, 550, 560, 575, 600, 625, 640, 650, 675, 700, 720, 725, 750, 775, 800, 825, 850, 875, 880, 900, 925, 950, 960, 975, 1000, 1025 or 1040 mg, or approximately 1, approximately 2.5, approximately 5, approximately 7.5, approximately 10, approximately 15 Approximately 20, 25, 30, 35, 40, 45, 50, 55, 60, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 140, 150, 160, 170, 175, 180, 190, 200, 225, 240, 250, 275, 300, 320, 325, 350, 375, 400, 4 The crystalline material can be contained in one of the following amounts: 25, approximately 450, approximately 475, approximately 480, approximately 500, approximately 525, approximately 550, approximately 560, approximately 575, approximately 600, approximately 625, approximately 640, approximately 650, approximately 675, approximately 700, approximately 720, approximately 725, approximately 750, approximately 775, approximately 800, approximately 825, approximately 850, approximately 875, approximately 880, approximately 900, approximately 925, approximately 950, approximately 960, approximately 975, approximately 1000, approximately 1025, or approximately 1040 mg. For example, the dose can contain the crystalline material in an amount of 10 mg or approximately 10 mg. The dose can contain the crystalline material in an amount of 15 mg or approximately 15 mg. The dose can contain the crystalline material in an amount of 20 mg or approximately 20 mg. The dose can contain the crystalline material in an amount of 30 mg or approximately 30 mg. The dosage may include 40 mg or approximately 40 mg of crystals. The dosage may include 50 mg or approximately 50 mg of crystals. The dosage may include 75 mg or approximately 75 mg of crystals. The dosage may include 80 mg or approximately 80 mg of crystals.The dosage can include 100 mg or approximately 100 mg of crystals. The dosage can include 120 mg or approximately 120 mg of crystals. The dosage can include 160 mg or approximately 160 mg of crystals. The dosage can include 240 mg or approximately 240 mg of crystals. The dosage can include 320 mg or approximately 320 mg of crystals. The dosage can include 400 mg or approximately 400 mg of crystals. The dosage can include 480 mg or approximately 480 mg of crystals. The dosage can include 560 mg or approximately 560 mg of crystals. The dosage can include 640 mg or approximately 640 mg of crystals. The dosage can include 720 mg or approximately 720 mg of crystals. The dosage can include 800 mg or approximately 800 mg of crystals. The dosage can include 880 mg or approximately 880 mg of crystals. The dosage can include 960 mg or approximately 960 mg of crystals. The dosage can also include 1040 mg or approximately 1040 mg of crystals.

[0087] In various embodiments, the dose, for example, a unit dose for daily administration, may be one of the following amounts: approximately 320 mg, approximately 400 mg, approximately 480 mg, approximately 560 mg, approximately 640 mg, approximately 720 mg, approximately 800 mg, approximately 880 mg, approximately 960 mg, or approximately 1040 mg, or an amount within a range between any two of the above values, containing the crystalline material.

[0088] In various embodiments, the dose, for example, a unit dose for daily administration, can be one of the following amounts of crystalline material: approximately 400 mg, approximately 480 mg, approximately 560 mg, approximately 640 mg, approximately 720 mg, approximately 800 mg, approximately 880 mg, approximately 960 mg, or approximately 1040 mg.

[0089] In various embodiments, the dose, such as a unit dose for daily administration, can be an amount of crystalline material ranging from about 320 mg to one of about 400 mg, about 480 mg, about 560 mg, about 640 mg, about 720 mg, about 800 mg, about 880 mg, about 960 mg, or about 1040 mg.

[0090] In various embodiments, the dose, for example, a unit dose for daily administration, can be an amount of crystalline material containing the crystalline material in a range between approximately 400 mg, approximately 480 mg, approximately 560 mg, approximately 640 mg, approximately 720 mg, approximately 800 mg, approximately 880 mg, approximately 960 mg, or approximately 1040 mg, or any two of the above values.

[0091] In one embodiment, the unit dose may contain the crystals in any of the individual values ​​(mg) cited in the preceding paragraph, for example, ±1%, ±2%, ±2.5%, ±5%, ±7.5%, ±10%, ±15%, ±20%, ±25%, ±30%, ±40%, or ±50%, or in any percentage range independently selected from any of the following: about ±1%, about ±2%, about ±2.5%, about ±5%, about ±7.5%, about ±10%, about ±15%, about ±20%, about ±25%, about ±30%, about ±40%, or about ±50%. For example, the range may be ±1% or about ±1%. The range may be ±2% or about ±2%. The range may be ±2.5% or about ±2.5%. The range may be ±5% or about ±5%. The range may be ±7.5% or approximately ±7.5%. The range may be ±10% or approximately ±10%. The range may be ±15% or approximately ±15%. The range may be ±20% or approximately ±20%. The range may be ±25% or approximately ±25%. The range may be ±30% or approximately ±30%. The range may be ±40% or approximately ±40%. The range may be ±50% or approximately ±50%.

[0092] Furthermore, for example, a unit dose may contain one amount of crystals from among 10 mg ± 1%, 10 mg ± 2%, 10 mg ± 2.5%, 10 mg ± 5%, 10 mg ± 7.5%, 10 mg ± 10%, 10 mg ± 15%, 10 mg ± 20%, 10 mg ± 25%, 10 mg ± 30%, 10 mg ± 40%, or 10 mg ± 50%. A unit dose may contain one amount of crystals from among 15 mg ± 1%, 15 mg ± 2%, 15 mg ± 2.5%, 15 mg ± 5%, 15 mg ± 7.5%, 15 mg ± 10%, 15 mg ± 15%, 15 mg ± 20%, 15 mg ± 25%, 15 mg ± 30%, 15 mg ± 40%, or 15 mg ± 50%. The unit dose may contain one amount of crystals from among 20 mg ± 1%, 20 mg ± 2%, 20 mg ± 2.5%, 20 mg ± 5%, 20 mg ± 7.5%, 20 mg ± 10%, 20 mg ± 15%, 20 mg ± 20%, 20 mg ± 25%, 20 mg ± 30%, 20 mg ± 40%, or 20 mg ± 50%. The unit dose may contain one amount of crystals from among 30 mg ± 1%, 30 mg ± 2%, 30 mg ± 2.5%, 30 mg ± 5%, 30 mg ± 7.5%, 30 mg ± 10%, 30 mg ± 15%, 30 mg ± 20%, 30 mg ± 25%, 30 mg ± 30%, 30 mg ± 40%, or 30 mg ± 50%. The unit dose may contain one amount of crystals from among 40 mg ± 1%, 40 mg ± 2%, 40 mg ± 2.5%, 40 mg ± 5%, 40 mg ± 7.5%, 40 mg ± 10%, 40 mg ± 15%, 40 mg ± 20%, 40 mg ± 25%, 40 mg ± 30%, 40 mg ± 40%, or 40 mg ± 50%. The unit dose may contain one amount of crystals from among 50 mg ± 1%, 50 mg ± 2%, 50 mg ± 2.5%, 50 mg ± 5%, 50 mg ± 7.5%, 50 mg ± 10%, 50 mg ± 15%, 50 mg ± 20%, 50 mg ± 25%, 50 mg ± 30%, 50 mg ± 40%, or 50 mg ± 50%. The unit dose may contain one of the following amounts of crystalline material: 60 mg ± 1%, 60 mg ± 2%, 60 mg ± 2.5%, 60 mg ± 5%, 60 mg ± 7.5%, 60 mg ± 10%, 60 mg ± 15%, 60 mg ± 20%, 60 mg ± 25%, 60 mg ± 30%, 60 mg ± 40%, or 60 mg ± 50%.The unit dose may contain one amount of crystals from among 75 mg ± 1%, 75 mg ± 2%, 75 mg ± 2.5%, 75 mg ± 5%, 75 mg ± 7.5%, 75 mg ± 10%, 75 mg ± 15%, 75 mg ± 20%, 75 mg ± 25%, 75 mg ± 30%, 75 mg ± 40%, or 75 mg ± 50%. The unit dose may contain one amount of crystals from among 80 mg ± 1%, 80 mg ± 2%, 80 mg ± 2.5%, 80 mg ± 5%, 80 mg ± 7.5%, 80 mg ± 10%, 80 mg ± 15%, 80 mg ± 20%, 80 mg ± 25%, 80 mg ± 30%, 80 mg ± 40%, or 80 mg ± 50%. The unit dose may contain one amount of crystals from among 100 mg ± 1%, 100 mg ± 2%, 100 mg ± 2.5%, 100 mg ± 5%, 100 mg ± 7.5%, 100 mg ± 10%, 100 mg ± 15%, 100 mg ± 20%, 100 mg ± 25%, 100 mg ± 30%, 100 mg ± 40%, or 100 mg ± 50%. The unit dose may contain one amount of crystals from among 120 mg ± 1%, 120 mg ± 2%, 120 mg ± 2.5%, 120 mg ± 5%, 120 mg ± 7.5%, 120 mg ± 10%, 120 mg ± 15%, 120 mg ± 20%, 120 mg ± 25%, 120 mg ± 30%, 120 mg ± 40%, or 120 mg ± 50%. The unit dose may contain one amount of crystals from among 160 mg ± 1%, 160 mg ± 2%, 160 mg ± 2.5%, 160 mg ± 5%, 160 mg ± 7.5%, 160 mg ± 10%, 160 mg ± 15%, 160 mg ± 20%, 160 mg ± 25%, 160 mg ± 30%, 160 mg ± 40%, or 160 mg ± 50%. The unit dose may contain one amount of crystals from among 240 mg ± 1%, 240 mg ± 2%, 240 mg ± 2.5%, 240 mg ± 5%, 240 mg ± 7.5%, 240 mg ± 10%, 240 mg ± 15%, 240 mg ± 20%, 240 mg ± 25%, 240 mg ± 30%, 240 mg ± 40%, or 240 mg ± 50%. The unit dose may contain one amount of crystals from among 320 mg ± 1%, 320 mg ± 2%, 320 mg ± 2.5%, 320 mg ± 5%, 320 mg ± 7.5%, 320 mg ± 10%, 320 mg ± 15%, 320 mg ± 20%, 320 mg ± 25%, 320 mg ± 30%, 320 mg ± 40%, or 320 mg ± 50%.The unit dose may contain one amount of crystals from among 400 mg ± 1%, 400 mg ± 2%, 400 mg ± 2.5%, 400 mg ± 5%, 400 mg ± 7.5%, 400 mg ± 10%, 400 mg ± 15%, 400 mg ± 20%, 400 mg ± 25%, 400 mg ± 30%, 400 mg ± 40%, or 400 mg ± 50%. The unit dose may contain one amount of crystals from among 480 mg ± 1%, 480 mg ± 2%, 480 mg ± 2.5%, 480 mg ± 5%, 480 mg ± 7.5%, 480 mg ± 10%, 480 mg ± 15%, 480 mg ± 20%, 480 mg ± 25%, 480 mg ± 30%, 480 mg ± 40%, or 480 mg ± 50%. The unit dose may contain one amount of crystals from among 560 mg ± 1%, 560 mg ± 2%, 560 mg ± 2.5%, 560 mg ± 5%, 560 mg ± 7.5%, 560 mg ± 10%, 560 mg ± 15%, 560 mg ± 20%, 560 mg ± 25%, 560 mg ± 30%, 560 mg ± 40%, or 560 mg ± 50%. The unit dose may contain one amount of crystals from among 640 mg ± 1%, 640 mg ± 2%, 640 mg ± 2.5%, 640 mg ± 5%, 640 mg ± 7.5%, 640 mg ± 10%, 640 mg ± 15%, 640 mg ± 20%, 640 mg ± 25%, 640 mg ± 30%, 640 mg ± 40%, or 640 mg ± 50%. The unit dose may contain one amount of crystals from among 720 mg ± 1%, 720 mg ± 2%, 720 mg ± 2.5%, 720 mg ± 5%, 720 mg ± 7.5%, 720 mg ± 10%, 720 mg ± 15%, 720 mg ± 20%, 720 mg ± 25%, 720 mg ± 30%, 720 mg ± 40%, or 720 mg ± 50%. The unit dose may contain one amount of crystals from among 800 mg ± 1%, 800 mg ± 2%, 800 mg ± 2.5%, 800 mg ± 5%, 800 mg ± 7.5%, 800 mg ± 10%, 800 mg ± 15%, 800 mg ± 20%, 800 mg ± 25%, 800 mg ± 30%, 800 mg ± 40%, or 800 mg ± 50%.The unit dose may contain one amount of crystals from among 880 mg ± 1%, 880 mg ± 2%, 880 mg ± 2.5%, 880 mg ± 5%, 880 mg ± 7.5%, 880 mg ± 10%, 880 mg ± 15%, 880 mg ± 20%, 880 mg ± 25%, 880 mg ± 30%, 880 mg ± 40%, or 880 mg ± 50%. The unit dose may contain one amount of crystals from among 960 mg ± 1%, 960 mg ± 2%, 960 mg ± 2.5%, 960 mg ± 5%, 960 mg ± 7.5%, 960 mg ± 10%, 960 mg ± 15%, 960 mg ± 20%, 960 mg ± 25%, 960 mg ± 30%, 960 mg ± 40%, or 960 mg ± 50%. The unit dose may contain one amount of crystals from among 1040 mg ± 1%, 1040 mg ± 2%, 1040 mg ± 2.5%, 1040 mg ± 5%, 1040 mg ± 7.5%, 1040 mg ± 10%, 1040 mg ± 15%, 1040 mg ± 20%, 1040 mg ± 25%, 1040 mg ± 30%, 1040 mg ± 40%, or 1040 mg ± 50%.

[0093] A unit dose, for example, a unit dose for daily administration, is at least one of approximately 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 ng / ml, or a concentration greater than or equal to any two of the above concentrations, e.g. For example, C in the plasma of individuals with C levels of 700-1500, 700-900, 800-1300, 750-950, 800-1000, 850-950, 850-1050, 900-1400, 900-1300, 900-1200, 900-1100, 950-1050, 950-1400, 950-1150, 1000-1400, 1000-1300, 1000-1200, 700-2500, 1000-2500, 1500-2500, 1500-2000, 1500-2500 and 2000-2500 ng / ml max It may contain an effective amount of crystals for administration to an individual, resulting in a concentration of (ng / ml). For example, Cmax can be 700 ng / ml, approximately 700 ng / ml, or approximately 700 ng / ml or more. C max can be 750 ng / ml, approximately 750 ng / ml, or approximately 750 ng / ml or more. C max can be 800 ng / ml, approximately 800 ng / ml, or approximately 800 ng / ml or more. C max can be 850 ng / ml, approximately 850 ng / ml, or approximately 850 ng / ml or more. C max can be 900 ng / ml, approximately 900 ng / ml, or approximately 900 ng / ml or more. C max can be 950 ng / ml, approximately 950 ng / ml, or approximately 950 ng / ml or more. C max can be 1000 ng / ml, approximately 1000 ng / ml, or approximately 1000 ng / ml or more. C max can be 1050 ng / ml, approximately 1050 ng / ml, or approximately 1050 ng / ml or more. C max can be 1100 ng / ml, approximately 1100 ng / ml, or approximately 1100 ng / ml or more. C max can be 1200 ng / ml, approximately 1200 ng / ml, or approximately 1200 ng / ml or more. C max can be 1300 ng / ml, approximately 1300 ng / ml, or approximately 1300 ng / ml or more. C max can be 1400 ng / ml, approximately 1400 ng / ml, or approximately 1400 ng / ml or more. C max can be 1500 ng / ml, approximately 1500 ng / ml, or approximately 1500 ng / ml or more. C max can be 1600 ng / ml, approximately 1600 ng / ml, or approximately 1600 ng / ml or more. C max can be 1700 ng / ml, approximately 1700 ng / ml, or approximately 1700 ng / ml or more. C maxThis may be 1800 ng / ml, approximately 1800 ng / ml, or approximately 1800 ng / ml or more. max This may be 1900 ng / ml, approximately 1900 ng / ml, or approximately 1900 ng / ml or more. max This could be 2000 ng / ml, approximately 2000 ng / ml, or approximately 2000 ng / ml or more. max This may be 2100 ng / ml, approximately 2100 ng / ml, or approximately 2100 ng / ml or more. max This may be 2200 ng / ml, approximately 2200 ng / ml, or approximately 2200 ng / ml or more. max This could be 2300 ng / ml, approximately 2300 ng / ml, or approximately 2300 ng / ml or more. max This could be 2400 ng / ml, approximately 2400 ng / ml, or approximately 2400 ng / ml or more. max This could be 2500 ng / ml, approximately 2500 ng / ml, or approximately 2500 ng / ml or more.

[0094] A unit dose, for example, a unit dose for daily administration, is at least one of approximately 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, or 1500 ng / ml of plasma C of an individual, or a range between any two of the aforementioned concentrations. max It can contain an effective amount of crystals for administration to individuals that yield (ng / ml).

[0095] The unit dose, for example, the unit dose for daily administration, is the plasma C of an individual, ranging from at least one of the following as the lower limit: approximately 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, or 1450 ng / ml, to an upper limit of approximately 1500. maxIt can contain an effective amount of crystals for administration to individuals that yield (ng / ml).

[0096] A unit dose, for example, a unit dose for daily administration, is at least one of approximately 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 ng / ml of plasma C in an individual, or in a range between any two of the aforementioned concentrations. max It can contain an effective amount of crystals for administration to individuals that yield (ng / ml).

[0097] A unit dose, for example, a unit dose for daily administration, is at least one of approximately 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 ng / ml of plasma C in an individual, or in a range between any two of the aforementioned concentrations. max It can contain an effective amount of crystals for administration to individuals that yield (ng / ml).

[0098] The unit dose, for example, the unit dose for daily administration, is at least 1500 ng / ml and the plasma C of an individual in the range of 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, or 2500 ng / ml. max It can contain an effective amount of crystals for administration to individuals that yield (ng / ml).

[0099] A unit dose, for example, a unit dose for daily administration, is the amount of C in the plasma of an individual. max It is possible to contain an effective amount of crystals for administration to an individual that yields (ng / ml), and the C maxThis corresponds to plasma-adjusted concentrations effective in inhibiting αvβ6 or αvβ1 (%) in individuals at least one of 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 97, 98, 99, or 100%, or at least one of approximately 50, approximately 55, approximately 60, approximately 65, approximately 70, approximately 75, approximately 80, approximately 85, approximately 90, approximately 95, approximately 97, approximately 98, approximately 99, or approximately 100%, or a range between any two of the above percentages, for example, 50-100, 60-90, 70-90, 75-95, 90-95, 90-98, 90-99%. In some embodiments, the crystal may be an αvβ6 / αvβ1 biinhibitor, C maxThis can correspond to plasma-modified concentrations effective in inhibiting αvβ6 and αvβ1 in individuals at each percentage independently selected from the aforementioned percentages or a range between any two of the aforementioned percentages. For example, a plasma-modified concentration may be effective in inhibiting αvβ6 by at least about 50%. A plasma-modified concentration may be effective in inhibiting αvβ6 by at least about 60%. A plasma-modified concentration may be effective in inhibiting αvβ6 by at least about 70%. A plasma-modified concentration may be effective in inhibiting αvβ6 by at least about 80%. A plasma-modified concentration may be effective in inhibiting αvβ6 by at least about 90%. A plasma-modified concentration may be effective in inhibiting αvβ6 by at least about 95%. A plasma-modified concentration may be effective in inhibiting αvβ6 by at least about 97%. A plasma-modified concentration may be effective in inhibiting αvβ6 by at least about 98%. A plasma-modified concentration may be effective in inhibiting αvβ6 by at least about 99%. A plasma-modified concentration may be effective in inhibiting αvβ6 by approximately 100%. Furthermore, for example, a plasma-modified concentration may be effective in inhibiting αvβ1 by at least approximately 50%. A plasma-modified concentration may be effective in inhibiting αvβ1 by at least approximately 60%. A plasma-modified concentration may be effective in inhibiting αvβ1 by at least approximately 70%. A plasma-modified concentration may be effective in inhibiting αvβ1 by at least approximately 80%. A plasma-modified concentration may be effective in inhibiting αvβ1 by at least approximately 90%. A plasma-modified concentration may be effective in inhibiting αvβ1 by at least approximately 95%. A plasma-modified concentration may be effective in inhibiting αvβ1 by at least approximately 97%. A plasma-modified concentration may be effective in inhibiting αvβ1 by at least approximately 98%. A plasma-modified concentration may be effective in inhibiting αvβ1 by at least approximately 99%. A plasma-modified concentration may be effective in inhibiting αvβ1 by approximately 100%. The phrase "αvβ6 and / or αvβ1 in each independently selected percentage of the subjects" means, in other words, an αvβ6 monoinhibitor and the corresponding percentage, an αvβ1 monoinhibitor and the corresponding percentage, or an αvβ6 / αvβ6 dual inhibitor and the corresponding independently selected percentage.

[0100] Dosage forms for daily administration can be administered once a day to individuals requiring it. That is, the total amount of crystals to be administered daily can be administered all at once each day. Alternatively, if it is desirable for the total amount of crystals to be administered in two or more doses per day, a dosage form containing an appropriate amount of crystals can be administered two or more times a day, for example, twice, three or four times a day.

[0101] Compositions comprising the crystalline materials disclosed herein are also described. In some embodiments, the composition is intended for use as a human or veterinary pharmaceutical. In some embodiments, the composition is intended for use in the methods described herein. In some embodiments, the composition is intended for use in the treatment of diseases or disorders described herein.

[0102] How to use The crystals and compositions disclosed herein can be used in methods of administration and treatment as provided herein. The crystals and compositions can also be used in in vitro methods for screening purposes and / or for performing quality control assays, for example, in vitro methods for administering compounds or compositions to cells.

[0103] In one embodiment, a method is provided for treating a fibrous disease in an individual in need of treatment, characterized by administering a therapeutically effective amount of the crystalline material disclosed herein (e.g., form I, form II, form III, or form IV) to the individual. In one embodiment, the individual is a human. The individual, for example, a human, may be a person in need of treatment, such as a person who has or is suspected of having a fibrous disease.

[0104] In one embodiment, a method is provided for delaying the onset and / or development of fibrous disease in an individual at risk of developing fibrous disease (e.g., a human), characterized by administering a therapeutically effective amount of the crystalline material disclosed herein (e.g., form I, form II, form III, or form IV) to the individual. Delaying the onset is understood to include prevention in cases where the individual has not yet developed fibrous disease. In one embodiment, an individual at risk of developing fibrous disease has or is suspected of having one or more risk factors for developing fibrous disease. Risk factors for fibrous disease include the individual's age (e.g., middle-aged or older adult), the presence of inflammation, having one or more genetic elements associated with the development of fibrous disease, a medical history such as treatment with drugs or methods thought to be associated with increased susceptibility to fibrosis (e.g., radiation therapy) or medical conditions thought to be associated with fibrosis, a smoking history, and occupational and / or environmental factors such as exposure to contaminants associated with the development of fibrous disease. In one embodiment, individuals at risk of developing fibrous disease are those who have or are suspected of having NAFLD, NASH, CKD, scleroderma, Crohn's disease, NSIP, PSC, PBC, or those who have or are suspected of having myocardial infarction.

[0105] In one embodiment, the fibrotic disease is fibrosis of tissues such as the lungs (pulmonary fibrosis), liver, skin, heart (cardiac fibrosis), kidneys (renal fibrosis), or gastrointestinal tract (gastrointestinal fibrosis).

[0106] In one embodiment, the fibrotic disease is pulmonary fibrosis (e.g., IPF), hepatic fibrosis, cutaneous fibrosis, scleroderma, cardiac fibrosis, renal fibrosis, gastrointestinal fibrosis, primary sclerosing cholangitis, or cholangiofibrosis (e.g., PBC).

[0107] In some embodiments, the fibrotic disease is pulmonary fibrosis, for example, idiopathic pulmonary fibrosis (IPF). In some embodiments, the pulmonary fibrosis is, for example, interstitial lung disease, radiation-induced pulmonary fibrosis, or systemic sclerosis-associated interstitial lung disease.

[0108] In some embodiments, the fibrous disease is primary sclerosing cholangitis or biliary fibrosis. In some embodiments, the fibrous disease is primary biliary cholangitis (also known as primary biliary cirrhosis) or biliary atresia.

[0109] In one embodiment, the fibrous disease is fibrous nonspecific interstitial pneumonia (NSIP).

[0110] In some embodiments, the fibrotic disease is hepatic fibrosis, such as infectious hepatic fibrosis (derived from pathogens, such as HCV, HBV, or parasites such as schistosomiasis), NASH, alcoholic fatty liver-induced hepatic fibrosis, and cirrhosis. In some embodiments, hepatic fibrosis is non-alcoholic fatty liver disease (NAFLD). In some embodiments, hepatic fibrosis is NASH.

[0111] In one embodiment, the fibrous disease is biliary fibrosis.

[0112] In some embodiments, the fibrous disease is renal fibrosis, such as diabetic nephrosclerosis, hypertensive nephrosclerosis, focal segmental glomerulosclerosis ("FSGS"), and acute kidney injury due to contrast-induced nephropathy. In some embodiments, the fibrous disease is diabetic nephropathy, diabetic kidney disease, or chronic kidney disease.

[0113] In some embodiments, the fibrous disease is characterized by one or more of the following: glomerulonephritis, end-stage renal disease, hearing loss, changes in the lens of the eye, hematuria, or proteinuria. In some embodiments, the fibrous disease is Alport syndrome.

[0114] In some embodiments, the fibrous disease is systemic and localized sclerosis or scleroderma, keloids and hypertrophic scars, or postoperative adhesions. In some embodiments, the fibrous disease is scleroderma or systemic sclerosis.

[0115] In one embodiment, the fibrous disease is atherosclerosis or restenosis.

[0116] In one embodiment, the fibrous disease is gastrointestinal fibrosis, such as Crohn's disease.

[0117] In one embodiment, the fibrous disease is cardiac fibrosis, such as post-myocardial infarction-induced fibrosis and hereditary cardiomyopathy.

[0118] In some embodiments, the method may be characterized by regulating the activity of at least one integrin in an individual in whom regulation of the activity of at least one integrin is required. For example, the method may include regulating the activity of αvβ6. The method may include regulating the activity of αvβ1. The method may include regulating the activities of both αvβ1 and αvβ6. Regulating the activity of at least one integrin may include, for example, inhibiting at least one integrin. The method may include administering to an individual an amount of crystals effective in regulating the activity of at least one integrin in the individual, for example, at least one of αvβ1 and αvβ6. An individual in whom regulation of the activity of at least one integrin may have any of the fibrous diseases or conditions described herein. For example, fibrous diseases or conditions include idiopathic pulmonary fibrosis, interstitial lung disease, radiation-induced pulmonary fibrosis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic liver disease-induced fibrosis, Alport syndrome, primary sclerosing cholangitis, primary biliary cholangitis (also known as primary biliary cirrhosis), biliary atresia, systemic sclerosis-associated interstitial lung disease, scleroderma (also known as systemic sclerosis), diabetic nephropathy, diabetic nephropathy, focal segmental glomerulosclerosis, chronic kidney disease, or Crohn's disease. The method may involve administering to an individual an amount of crystals effective in modulating the activity of at least one integrin, for example, αvβ1 and αvβ6, in an individual requiring treatment for NASH. The method may also involve administering to an individual an amount of crystals effective in modulating the activity of at least one integrin, for example, αvβ1 and αvβ6, in an individual requiring treatment for IPF.

[0119] Fibrous diseases can be primarily mediated by αvβ6, for example, idiopathic pulmonary fibrosis or renal fibrosis. Therefore, this method may include regulating the activity of αvβ6 to treat conditions primarily mediated by αvβ6, such as IPF. Fibrous diseases can be primarily mediated by αvβ1, for example, NASH. Therefore, this method may include regulating the activity of αvβ1 to treat conditions primarily mediated by αvβ1, such as NASH. Fibrous diseases can be mediated by both αvβ1 and αvβ6, for example, PSC or biliary atresia. Therefore, this method may include regulating the activity of αvβ1 and αvβ6 to treat conditions mediated by both αvβ1 and αvβ6.

[0120] This crystal may be an αvβ1 modulator, for example, an inhibitor. This crystal may be an αvβ6 modulator, for example, an inhibitor. This crystal may be a dual modulator of αvβ1 and αvβ6, for example, a dual inhibitor such as a biselective inhibitor.

[0121] Treating individuals with fibrous disease by modulating or inhibiting the activity of one or both of αvβ1 integrin and αvβ6 integrin means modulating or inhibiting αvβ1 integrin, αvβ6 integrin, or both αvβ1 and αvβ6 integrin to a degree sufficient to treat fibrous disease in the subject.

[0122] In one embodiment, a crystalline material (e.g., morphology I, morphology II, morphology III, or morphology IV) is provided for use in the treatment of fibrous diseases. The use of the crystalline material (e.g., morphology I, morphology II, morphology III, or morphology IV) in the manufacture of pharmaceuticals for the treatment of fibrous diseases is also provided.

[0123] In one embodiment, a method is provided for inhibiting αvβ6 integrin in an organism, comprising administering to the organism one of the crystals disclosed herein (e.g., form I, form II, form III, or form IV).

[0124] A method for inhibiting TGFβ activation in cells is also provided, comprising administering the cells with the crystals disclosed herein (e.g., morphology I, morphology II, morphology III, or morphology IV).

[0125] A method for inhibiting αvβ6 integrin in an individual requiring inhibition of αvβ6 integrin is also provided, comprising administering to the individual a crystalline substance disclosed herein (e.g., form I, form II, form III, or form IV). In one such method, the crystalline substance is a selective αvβ6 integrin inhibitor. In another such method, the crystalline substance does not substantially inhibit α4β1, αvβ8, and / or α2β3 integrins. In yet another such method, the crystalline substance inhibits αvβ6 integrin but not substantially inhibits α4β1 integrin. In yet another such method, the crystalline substance inhibits αvβ6 integrin but not substantially inhibits αvβ8 integrin. In yet another such method, the crystalline substance inhibits αvβ6 integrin but not substantially inhibits α2β3 integrin. In one embodiment, αvβ6 integrin, as well as one or more αvβ1, αvβ3, αvβ5, α2β1, α3β1, α6β1, α7β1, and α 11 A method for inhibiting β1 integrin is provided in individuals where this is necessary. In another embodiment, a method for inhibiting αvβ6 integrin and αvβ1 integrin is provided. In yet another embodiment, αvβ6 integrin, α V β3 integrin and α VA method for inhibiting β5 integrin is provided. In another embodiment, a method for inhibiting αvβ6 integrin and α2β1 integrin is provided. In another embodiment, a method for inhibiting αvβ6 integrin, α2β1 integrin and α3β1 integrin is provided. In another embodiment, a method for inhibiting αvβ6 integrin and α6β1 integrin is provided. In another embodiment, a method for inhibiting αvβ6 integrin and α7β1 integrin is provided. In another embodiment, αvβ6 integrin and α 11 A method for inhibiting β1 integrin is provided. In all of the above embodiments, in one embodiment, the method of inhibition is for an individual requiring inhibition, for example, an individual having or suspected of having a fibrotic disease, and the method comprises administering to the individual one of the crystals disclosed herein (for example, form I, form II, form III, or form IV).

[0126] In any of the methods described, in one aspect, the individual is a human being, for example, a human being who requires the method. The individual may be a human being diagnosed with or suspected of having a fibrous disease. The individual may be a human being who does not have a detectable disease but has one or more risk factors for developing a fibrous disease.

[0127] kit In another embodiment, the present invention further provides one or more of the crystalline materials disclosed herein (e.g., Form I, Form II, Form III, or Form IV) or a pharmaceutical composition comprising one or more of the crystalline materials disclosed herein. The kit can be used with any of the crystalline materials disclosed herein. The kit can be used for one or more of the uses described herein and may contain instructions for use in the treatment of fibrous diseases.

[0128] The kit generally includes suitable packaging. This kit may include one or more containers containing any of the compounds described herein. Each component (if there are two or more components) may be packed in a separate container, or several components may be combined into a single container if cross-reactivity and shelf life are acceptable. One or more components of the kit may be sterile and / or contained in sterile packaging.

[0129] The kit may be in unit dosage forms, bulk packages (e.g., repeated-dose packages), or subunit doses. For example, a kit may be provided containing a dose (e.g., a therapeutically effective dose) sufficient to effectively treat an individual over any of the following long periods, e.g., one week, two weeks, three weeks, four weeks, six weeks, eight weeks, three months, four months, five months, seven months, eight months, nine months, or longer, of the compounds disclosed herein and / or a second pharmaceutically active compound useful for the disease detailed herein (e.g., fibrosis). The kit may also include multiple unit doses of the crystalline material and instructions for use, and may be packaged in quantities sufficient for storage and use in pharmacies (e.g., hospital pharmacies) and dispensing pharmacies.

[0130] The kit may, as appropriate, include a series of instructions, general written instructions, regarding the use of the components of the method of the present invention, but an electronic storage medium (e.g., magnetic disk or optical disk) containing the instructions is also acceptable. The instructions included in the kit generally include information on the components and their administration to an individual. [Examples]

[0131] The following examples are provided to further aid in understanding the embodiments disclosed herein and assume an understanding of the prior art familiar to those skilled in the art related to the examples. The specific materials and conditions described in the specification are intended to illustrate specific aspects of the embodiments disclosed herein and should not be construed as limiting their reasonable scope.

[0132] The following abbreviations may be used herein: [Table 7]

[0133] This crystal was subjected to XRPD, DSC, TGA, DVS, using the procedure described below. 1 It is characterized by various analytical techniques, including 1H NMR and HPLC.

[0134] XRPD Unless otherwise specified, XRPD analysis was performed using a PANalytical Empyrean and an X'Pert3 X-ray powder diffractometer. The XRPD parameters used are shown in the table below. [Table 8]

[0135] TGA and DSC TGA data was collected using a TA Discovery 5500 / Q5000 TGA (TA Instruments). DSC was performed using a TA Discovery 2500 / Q2000 DSC (TA Instruments). The detailed parameters used are shown in the table below. [Table 9]

[0136] DVS DVS was measured using a DVS Intrinsic (SMS: Surface Measurement System). Relative humidity at 25°C was calibrated against the deliquescence points of LiCl, Mg(NO3)2, and KCl. The parameters for the DVS test are shown in the table below. [Table 10]

[0137] 1 1H NMR 1 ¹H NMR was collected using a Bruker 400 MHz NMR spectrometer with D2O as the solvent.

[0138] HPLC Detailed chromatographic conditions for measuring purity and stoichiometric ratio using Agilent HPLC are described in the table below. [Table 11] [Table 12]

[0139] Example 1. Preparation of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid can be produced using the method disclosed in US 20190276449.

[0140] Example 2. Salt test Salt screening experiments were conducted under 150 conditions using 30 salt-forming substances (e.g., bases and acids) in five different solvent systems (Table 5). Amorphous freeforms and their corresponding salt-forming substances were mixed in a 1:1 molar ratio in the five different solvent systems and then stirred at RT for approximately 5 days. After centrifugation, the resulting solids were vacuum-dried at RT for 4 hours and then analyzed by XRPD.

[0141] In five different solvent systems, a molar ratio of 1:2 (API / phosphate) did not generate any further phosphate forms.

[0142] Example 3. Preparation of Form I of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid free compound. Form I was prepared by mixing amorphous free (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid (~20 mg) with 4.3 mg of phosphoric acid (85%) and slurring in EtOH at RT for 5 days. The product was analyzed by XRPD, DSC, TGA, 1 Analysis was performed by 1H NMR and HPLC. The XRPD pattern is shown in Figure 1A. The TGA and DSC graphs are shown in Figure 1B. The TGA and DSC graphs showed a weight loss of 5.21% up to 150°C, with three endothermic peaks observed at 88.3, ​​136.3, and 197.6°C. 1 ¹H NMR (D2O) data showed 2.5 wt% residual EtOH. Based on HPLC / IC analysis, the molar ratio of API to acid was 1:1.

[0143] Form I in 100 mg scale was obtained by slurring amorphous free (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid (99.5 mg) and equimolar amounts of phosphoric acid (24.8 mg, 85%) in EtOH (2.5 mL) at a cycling temperature (0.05 °C / min from 50 °C to 5 °C, then 0.375 °C / min from 5 °C to 50 °C, 3 cycles). The product was analyzed by XRPD, DSC, TGA, 1 Analysis was performed by 1H NMR and HPLC. The XRPD pattern is shown in Figure 1A. TGA and DSC graphs are shown in Figure 1C. The TGA and DSC graphs showed a weight loss of 5.04% up to 110°C, with three endothermic peaks observed at 86.1, 140.8, and 197.0°C. 1 0.4 wt% residual EtOH was detected by 1H NMR (D2O). Based on HPLC / IC analysis, the molar ratio of API to phosphate was 1:1.

[0144] Form I on a 1g scale was obtained by slurring amorphous free (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid (1.04g) and equimolar amounts of phosphoric acid (232.9mg, 85%) together with seed crystals of Form I in anhydrous EtOH (≧99.7%) (25mL) at RT. The product was analyzed by XRPD, DSC, TGA, 1 Analysis was performed by 1H NMR and HPLC. The XRPD pattern is shown in Figure 1A. TGA and DSC graphs are shown in Figure 1D. The TGA and DSC graphs showed a weight loss of 10.23% up to 150°C, with three endothermic peaks observed at 77.3, 132.2, and 197.0°C. 1 0.2% by weight of residual EtOH was detected by 1H NMR (D2O). Based on HPLC / IC analysis, the molar ratio of API to phosphate was 1:0.9.

[0145] Form I on a 4.5g scale was obtained by slurring amorphous free (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid (4.5g) and equimolar amounts of 85% phosphoric acid (1.05g) in anhydrous EtOH (≧99.7%) (112mL) at RT, and adding approximately 1 wt% seed crystal of Form I. The product was obtained as XRPD, DSC, TGA, DVS, 1 Analysis was performed by 1H NMR and HPLC. The XRPD pattern is shown in Figure 1A. TGA and DSC graphs are shown in Figure 1E. The TGA and DSC graphs showed a weight loss of 7.37% up to 150°C, with three endothermic peaks observed at 95.2, 134.1, and 200.9°C. 1 ¹H NMR (D2O) revealed 2 wt% residual EtOH. Based on HPLC / IC analysis, the molar ratio of API to phosphate was 1:1. The DVS graph is shown in Figure 1F. It showed a water absorption rate of 16.4% at 25°C / 80%RH, and morphology I after the DVS test was deliquescent.

[0146] Example 4. Preparation of Form I from (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoate amphoteric ion. A method for preparing a solution of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoate amphoteric ion (ZI) / ethanol and converting the solution to form I is described below. [ka] Benzyl (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoate·2HCl (1×, 1 equivalent, uncorrected bulk content as assay content) was dissolved in concentrated HCl (2.06×) and stirred at approximately 28°C for approximately 18 hours. The mixture was diluted with water, and a mixture with a pH of ~7.2 was obtained using NaOH (50%, equivalent to the HCl used). Unreacted benzyl (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoate and impurities were removed by DCM extraction. Next, NaHCO3 (2 equivalents) was added as a solid to obtain a mixed aqueous solution with a pH of 7.2–7.6. BnOH and trace impurities were further removed using TBME. The ZI product was extracted from the mixed aqueous solution using DCM. The DCM solution of the wet product was dried by azeotropic distillation of DCM, followed by activated carbon treatment and polish filtration. The product filtrate was concentrated under vacuum and captured in anhydrous ethanol to remove residual DCM. The final ZI was adjusted to approximately 20 wt% using anhydrous ethanol for subsequent crystallization. The overall yield was estimated to be 84–89% (uncorrected from starting materials), and the AUC purity was >98%. Residual DCM was less than 0.4%, KF was less than 0.1%, and residual sodium was less than 250 ppm. This process was demonstrated on a ~50 g scale. [ka] (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoate ZI was dissolved in 1:4 MeOH / EtOH (v / v, 7.32x by weight). A phosphoric acid solution in 1:4 MeOH / EtOH (v / v, 0.25 equivalents relative to ZI) was slowly added to the ZI solution at 30°C (with good stirring). Seed crystals of morph I (2-3%) were added to obtain a suspension. Then, morph I was gradually precipitated by slowly adding phosphoric acid solution / 1:4 MeOH / EtOH (0.8 eq.) (with good stirring). After the addition of phosphoric acid was complete, the batch was aged at 30°C for a minimum of 2 hours, followed by 20°C for a minimum of 2 hours. The final product was filtered by vacuum filtration under nitrogen protection and then washed with pure EtOH. The wet product was vacuum-dried at 35–40°C, and the resulting cake was conditioned with wet N2 (NMT 60% RH) at atmospheric pressure to obtain morphological I crystals as an off-white powder. The overall yield was 85–90%, and the purity of the AUC product was >99%. The residual EtOH in the product was <0.5 wt% (specification: NMT 0.5 wt%), and the moisture content was ~3% (target 3 ± 0.5 wt%) as determined by Karl Fischer titration. This process was demonstrated on a 40–50 g scale and applied to 1.5 kg batches.

[0147] Example 5. Preparation of Form II from (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid Form II was prepared by mixing amorphous free (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid (~20 mg) with fumaric acid (4.7 mg) and slurring it in acetone / H2O (19:1, v:v) using a temperature cycle (0.05 °C / min from 50 °C to 5 °C, then 0.375 °C / min from 5 °C to 50 °C, 3 cycles). The product was analyzed by XRPD. Form II was prepared again on a 100 mg scale by slurring amorphous free (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid (101.9 mg) and fumaric acid (11.7 mg) in acetone / H2O (19:1,v:v) (2.5 mL) using a temperature cycle (0.05 °C / min from 50 °C to 5 °C, then 0.375 °C / min from 5 °C to 50 °C, 3 cycles). The product was analyzed by XRPD, DSC, TGA and 1 Analysis was performed by 1H NMR. The XRPD patterns of Form II prepared on a 20 mg and 100 mg scale are shown in Figure 2A. The TGA and DSC graphs of Form II prepared on a 100 mg scale are shown in Figure 2B. The TGA and DSC graphs showed a weight loss of 13.02% up to 125°C, with one endothermic peak observed at 95.4°C. 1 1HNMR (D2O) data showed a molar ratio of API to fumaric acid of 1:0.6, and 1.9 wt% residual acetone was observed.

[0148] Heating experiments were conducted on morphology II, and measurements were taken using XRPD. After heating the sample to 150°C, an amorphous sample was obtained. The XRPD results are shown in Figure 2C.

[0149] Example 6. Preparation of Form III from (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid Form III was prepared by mixing amorphous free (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid (~20 mg) with 1,5-naphthalenedisulfonic acid (16.9 mg) and slurring in ethyl acetate at RT for 5 days. The product was analyzed by XRPD, DSC, TGA and 1 Analysis was performed by 1H NMR. The XRPD pattern of morphology III is shown in Figure 3A. The TGA and DSC graphs of morphology III are shown in Figure 3B. The TGA and DSC graphs showed a weight loss of 11.11% up to 150°C, with one endothermic peak observed at 103.4°C. 1 The HNMR (D2O) data showed a molar ratio of API to acid of 1:1.1 and no residual siRNA signal was observed.

[0150] Example 7. Preparation of Form IV from (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid (100 mg) and phosphoric acid (20 mg) (1:1 molar ratio) were dissolved in iPA (3.3 ml) and MeOH (4.0 ml). The clear solution was evaporated at 50°C to obtain a crystalline solid. PXRD was collected from the bulk solid, and several large plates were isolated and used for single-crystal X-ray crystallography.

[0151] For crystal screening / evaluation and diffraction data collection, a Bruker D8 QUEST single-crystal X-ray diffractometer equipped with a high-brightness IμS 3.0 microfocus (50kV x 1mA) for Cu radiation (λ=1.54178Å) and a PHOTONII Charge-Integraing Pixel Array detector offering superior speed, sensitivity, and accuracy was used. X-ray diffraction data were collected using crystals cooled to 173K. The crystal structure analyzed using this dataset was a mixed solvate of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid monophosphate with iPA and water, in a molar ratio of salt:iPA:water = 2:1:1. The simulated XRPD pattern obtained from the crystal structure matched the bulk pattern, indicating that the bulk solid and single crystal have the same crystal structure. The experimental XRPD pattern and the simulated XRPD pattern are shown in Figure 4.

[0152] The crystal data is shown in Table 6. [Table 13]

[0153] Example 8. Solubility Test The approximate solubility of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyrizin-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid was measured by RT. Approximately 2 mg of the solid was placed in a 3 mL glass vial. Then, various solvents were added to the vial in stages (50-50-200-700 μL for each stage), and the mixture was stirred until the solid dissolved or the total volume reached 1 mL. The solubility results are shown in Table 7A. [Table 14]

[0154] The approximate solubility of Form I was determined by RT (Resolution Test). Approximately 2 mg of the solid was placed in a 3 mL glass vial. Then, various solvents were added to the vial in stages until the solid was dissolved or the total volume reached 1 mL (each stage being 50-50-200-700 μL). The solubility results are shown in Table 7B. [Table 15]

[0155] Example 9. Polymorphism Test For morphology I, 100 polymorph screening experiments were performed using methods including poor solvent addition, slurry formation under RT / 50°C / temperature cycles, solid vapor diffusion, liquid vapor diffusion, and slow evaporation.

[0156] Addition of poor solvent: Approximately 20 mg of Form I was dissolved in 1 mL of solvent. This solution was filtered through a PTFE membrane (pore size 0.45 μM) to obtain a clear solution. The solution was then magnetically stirred (~750 rpm) and the poor solvent was slowly added until a precipitate formed or the total volume of the poor solvent reached 5 mL. The resulting precipitate was isolated for XRPD analysis.

[0157] Slurry preparation in RT: Approximately 20 mg of Form I was suspended in 1 mL of the corresponding solvent in an HPLC vial. The suspension was magnetically stirred (~750 rpm) in RT for approximately 7 days, and the residual solid was isolated for XRPD analysis.

[0158] Slurry formation at 50°C: Approximately 20 mg of Form I was suspended in 1 mL of the corresponding solvent in an HPLC vial. The suspension was magnetically stirred (~750 rpm) at 50°C for approximately 7 days, and the resulting solid form was Form I.

[0159] Liquid vapor diffusion: Approximately 15 mg of Form I was dissolved in 1 mL of a suitable solvent in a 3 mL vial. This solution was filtered through a PTFE membrane (pore size 0.45 μM) into another clean glass vial to obtain a clear solution. The glass vial containing the clear solution was then placed in a 20 mL vial containing the corresponding volatile poor solvent (4 mL). The 20 mL vial was sealed with a cap and stored at room temperature for a sufficient time for the organic solvent vapor to interact with the solution. A clear solution or gel sample was obtained.

[0160] Solid vapor diffusion: Approximately 15 mg of Form I was weighed into a 3 mL glass vial. The 3 mL vial was then placed in a 20 mL vial containing the corresponding solvent (4 mL). The 20 mL vial was sealed with a cap and stored at RT. After 7 days, the solid was isolated for XRPD analysis.

[0161] Temperature cycling: Approximately 20 mg of form I was suspended in 1 mL of solvent in an HPLC vial. This suspension was magnetically stirred (~750 rpm) at a rate of 0.05 °C / min from 50 °C to 5 °C, and then at a rate of 0.375 °C / min from 5 °C to 50 °C. This cycle was repeated three times. The resulting solid form was amorphous form I.

[0162] Slow evaporation: Approximately 15 mg of Form I was dissolved in 1 mL of solvent in a 3 mL glass vial. All samples were filtered using a PTFE membrane (pore size 0.45 μM), and the filtrate was used in the follow-up step. The vial was sealed with Parafilm (登録商標) The sample was sealed (with several pinholes). After obtaining the gel sample, the corresponding solvent was added and the sample was subjected to a temperature cycle.

[0163] A heating experiment was conducted on morphology I. No morphological change was observed even after heating to 110°C, and an amorphous sample was obtained after heating to 150°C.

[0164] Example 9. Solid-phase integrin αvβ 6 Binding assay Microplates were coated with recombinant human integrin αvβ6 (2 μg / mL) in PBS (100 μL / well, overnight at 25°C). The coating solution was removed and the plates were washed with washing buffer (0.05% Tween 20; 0.5 mM MnCl2; in 1x TBS). The plates were blocked at 37°C for 2 hours using 200 μL / well of blocking buffer (1% BSA; 5% sucrose; 0.5 mM MnCl2; in 1x TBS). The test compounds and diluted recombinant TGFβ1LAP (0.67 μg / mL) in binding buffer (0.05% BSA; 2.5% sucrose; 0.5 mM MnCl2; in 1x TBS) were added. The plates were incubated at 25°C for 2 hours, washed, and then incubated with biotin-anti-hLAP for 1 hour. The bound antibody was detected by peroxidase-labeled streptavidin. IC of the test compound 50 The values ​​were calculated using 4-parameter logistic regression analysis. IC was obtained as αvβ6 integrin inhibition of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridine-2-yl)butyl)amino)-2-(quinazoline-4-ylamino)butanoic acid. 50 The value was <50 nM.

[0165] All references throughout this document, including publications, patents, patent applications, and published patent applications, are incorporated herein by reference in their entirety.

[0166] Although the aforementioned invention is described in some detail by examples and embodiments for the purpose of clarifying understanding, it will be apparent to those skilled in the art that certain minor changes and modifications will be made. Therefore, the description and embodiments should not be construed as limiting the scope of the invention.

Claims

1. A crystalline form of a salt of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid or a solvate thereof.

2. The crystalline form of claim 1 , wherein the salt is a phosphate salt.

3. 3. The crystalline form of claim 2, characterized in that the crystalline form has an X-ray powder diffraction (XRPD) pattern including a peak at an angle 2θ of 4.31±0.2°.

4. 3. The crystalline form of claim 2, characterized in that the crystalline form has an X-ray powder diffraction (XRPD) pattern including peaks at angles 2θ of 4.31±0.2° and 6.76±0.2°.

5. The crystals, a. Peaks at angles 2θ of 4.31±0.2°, 6.76±0.2°, 18.89±0.2°, 21.29±0.2° and 23.16±0.2°; b. peaks at angles 2θ of 4.31±0.2°, 6.76±0.2°, 11.25±0.2°, 12.75±0.2°, 18.89±0.2°, 20.38±0.2°, 21.29±0.2°, 23.16±0.2°, 23.97±0.2° and 24.68±0.2°; or c. Peaks at angles 2θ of 4.31±0.2°, 6.76±0.2°, 8.55±0.2°, 10.04±0.2°, 11.25±0.2°, 12.75±0.2°, 13.76±0.2°, 17.20±0.2°, 18.02±0.2°, 18.89±0.2°, 20.38±0.2°, 21.29±0.2°, 23.16±0.2°, 23.97±0.2°, 24.68±0.2°, 25.50±0.2°, 26.18±0.2°, 29.88±0.2° and 33.49±0.2°; 3. The crystalline form of claim 2, characterized in that it has an X-ray powder diffraction (XRPD) pattern comprising:

6. The crystals, a. endothermic peaks at about 88.3° C., about 136.3° C., and / or about 197.6° C. as determined by DSC; b. endothermic peaks at about 86.1° C., about 140.8° C., and / or about 197.0° C. as determined by DSC; c. endothermic peaks at about 77.3° C., about 132.2° C., and / or about 197.0° C. as determined by DSC; or d. endothermic peaks at about 95.2° C., about 134.1° C. and / or about 200.9° C. as determined by DSC; The crystal according to any one of claims 2 to 5, characterized in that it has

7. The crystals, a. about 5.21% weight loss after heating from about 26.5° C. to about 150.0° C. as determined by TGA; b. about 5.04% weight loss after heating from about 27.0° C. to about 110.0° C. as determined by TGA; c. a weight loss of about 10.32% upon heating from about 30.0° C. to about 150.0° C. as determined by TGA; or d. about 7.37% weight loss upon heating from about 27.0° C. to about 150.0° C. as determined by TGA; The crystal according to any one of claims 2 to 5, characterized in that it exhibits the following formula:

8. 3. The crystalline form of claim 2, wherein the crystalline form is a phosphate hydrate.

9. 9. The crystalline form of claim 8, wherein the crystalline form has a moisture content of about 3% by weight.

10. 2. The crystalline form of claim 1, wherein the salt is a fumarate salt.

11. 11. The crystalline form of claim 10, wherein the crystalline form has an XRPD pattern including a peak at an angle 2θ of 8.47±0.2°.

12. 11. The crystalline form of claim 10, wherein the crystalline form has an XRPD pattern including peaks at angles 2θ of 8.47±0.2° and 9.37±0.2°.

13. The crystals, a. Peaks at angles 2θ of 8.47±0.2°, 10.51±0.2°, 13.98±0.2°, 23.70±0.2° and 24.43±0.2°; b. peaks at angles 2θ of 8.47±0.2°, 9.37±0.2°, 10.51±0.2°, 13.98±0.2°, 16.20±0.2°, 17.26±0.2°, 23.70±0.2°, 24.01±0.2°, 24.43±0.2° and 25.59±0.2°; or c. Peaks at angles 2θ of 6.87±0.2°, 8.47±0.2°, 9.37±0.2°, 10.51±0.2°, 12.20±0.2°, 12.63±0.2°, 13.34±0.2°, 13.98±0.2°, 16.20±0.2°, 17.26±0.2°, 18.11±0.2°, 18.72±0.2°, 19.42±0.2°, 20.46±0.2°, 21.87±0.2°, 22.15±0.2°, 23.70±0.2°, 24.01±0.2°, 24.43±0.2° and 25.59±0.2°; 11. The crystalline form of claim 10, characterized in that it has an XRPD pattern comprising: 。

14. The crystals, a. having an endothermic peak at about 95.4°C as measured by DSC; or b. exhibiting a weight loss of about 13.02% upon heating from about 26.0° C. to about 125.0° C. as measured by TGA; The crystal according to any one of claims 10 to 13, characterized in that

15. 2. The crystalline form of claim 1, wherein the salt is a 1,5-naphthalenedisulfonate salt.

16. 16. The crystalline form of claim 15, wherein the crystalline form has an XRPD pattern including a peak at an angle 2θ of 12.58±0.2°.

17. 16. The crystalline form of claim 15, wherein the crystalline form has an XRPD pattern including peaks at angles 2θ of 12.58±0.2° and 15.87±0.2°.

18. The crystals, a. Peaks at angles 2θ of 15.87±0.2° and 23.85±0.2°; b. peaks at angles 2θ of 12.58±0.2°, 15.87±0.2°, 16.77±0.2°, 23.85±0.2° and 31.95±0.2°; or c. Peaks at angles 2θ of 3.17±0.2°, 12.58±0.2°, 15.87±0.2°, 16.77±0.2°, 18.78±0.2°, 23.85±0.2°, 25.30±0.2°, 27.34±0.2°, 29.61±0.2°, 31.95±0.2°, 38.05±0.2° and 38.63±0.2°; 16. The crystalline form of claim 15, characterized in that it has an XRPD pattern comprising:

19. The crystals, a. having an endothermic peak at about 103.4°C as determined by DSC; or b. exhibiting a weight loss of about 11.11% upon heating from about 23.0° C. to about 150.0° C. as determined by TGA; The crystal according to any one of claims 15 to 18, characterized in that

20. 2. The crystalline form of claim 1, wherein the crystalline form is a mixed solvate of a phosphate salt in isopropyl alcohol and water.

21. 21. The crystalline form of claim 20, wherein the crystalline form has an XRPD pattern including a peak at an angle 2θ of 4.14±0.2°.

22. 21. The crystalline form of claim 20, wherein the crystalline form has an XRPD pattern including peaks at angles 2θ of 4.14±0.2° and 6.64±0.2°.

23. 21. The crystalline form of claim 20, characterized in that the crystalline form has an XRPD pattern including peaks at angles 2θ of 4.14±0.2°, 20.02±0.2°, 21.57±0.2°, 6.64±0.2° and 25.22±0.2°.

24. 21. The crystalline form of claim 20, wherein the ratio of phosphate to isopropyl alcohol to water is about 2:1:

1.

25. 3. A method for preparing the crystalline form of claim 2, comprising the step of preparing a mixture of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid and phosphoric acid in a solvent.

26. 3. A method for preparing the crystalline form of claim 2, comprising converting the zwitterion of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid (ZI) into the crystalline form.

27. 21. A method for preparing the crystalline form of claim 20, comprising the step of preparing a mixture of (S)-4-((2-methoxyethyl)(4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butyl)amino)-2-(quinazolin-4-ylamino)butanoic acid and phosphoric acid in a solvent comprising isopropyl alcohol.

28. 10. A pharmaceutical composition comprising the crystalline form of claim 1 and a pharma- ceutically acceptable carrier or excipient.

29. A medicament for treating a fibrotic disease in an individual in need thereof, comprising a crystalline form according to any one of claims 1 to 24.

30. 30. The pharmaceutical of claim 29, wherein the fibrotic disease is pulmonary fibrosis, hepatic fibrosis, skin fibrosis, cardiac fibrosis, renal fibrosis, gastrointestinal fibrosis, primary sclerosing cholangitis or biliary fibrosis.

31. The pharmaceutical composition of claim 30, wherein the fibrotic disease is idiopathic pulmonary fibrosis, and the crystalline form is a phosphate hydrate characterized by having an X-ray powder diffraction (XRPD) pattern including peaks at angles 2θ of 4.31±0.2° and 6.76±0.2°.

32. 31. The pharmaceutical composition of claim 30, wherein the fibrotic disease is primary sclerosing cholangitis, and the crystalline form is a phosphate hydrate characterized by having an X-ray powder diffraction (XRPD) pattern including peaks at angles 2θ of 4.31±0.2° and 6.76±0.2°.

33. 31. The pharmaceutical composition of claim 30, wherein the fibrotic disease is idiopathic pulmonary fibrosis, and the crystalline form is a mixed solvate of isopropyl alcohol and water of the phosphate salt, characterized in having an XRPD pattern including peaks at angles 2θ of 4.14±0.2° and 6.64±0.2°.

34. 31. The pharmaceutical composition of claim 30, wherein the fibrotic disease is primary sclerosing cholangitis, and the crystalline form is a mixed solvate of the phosphate salt of isopropyl alcohol and water, characterized in having an XRPD pattern including peaks at angles 2θ of 4.14±0.2° and 6.64±0.2°.